Characterization of the physical properties and the bioavailability of phenobarbital tablets, USP, 100 mg by Sylvestri, Mario F.
University of the Pacific 
Scholarly Commons 
University of the Pacific Theses and 
Dissertations Graduate School 
1976 
Characterization of the physical properties and the bioavailability 
of phenobarbital tablets, USP, 100 mg 
Mario F. Sylvestri 
University of the Pacific 
Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Sylvestri, Mario F.. (1976). Characterization of the physical properties and the bioavailability of 
phenobarbital tablets, USP, 100 mg. University of the Pacific, Thesis. 
https://scholarlycommons.pacific.edu/uop_etds/434 
This Thesis is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been 
accepted for inclusion in University of the Pacific Theses and Dissertations by an authorized administrator of 
Scholarly Commons. For more information, please contact mgibney@pacific.edu. 
CHARACTERIZA'riON 0}' THE PHYSICAL PROPEH.TIES 
AND TlfE BIOAVAILABILITY OF 
PHENOBARBITAL TABLETS, USP, lOO.mg 
!: 
~, ,: 
A Thesis 
Presented to 
The Jt'acul ty of the Graduate School 
University of the Pacific 
In Part"ia1 ~<'ul:fillment · 
of the Requirements for the De~ree 
• ' • ! 
Master of Science 
, .. ,'. ..... 
by 
Mario F. Sylvestrj 
This thesis~ written and submitted by 
Matio F. Sylvestri 
is approved for recommendation to the Committee 
on Graduate Studies, University of the Pacific. 
Department Chairman or Dean: 
~W· 
Thesis Committee: 
Chairman 
Dated December 2, 1976 
--------------~-----------------------
I 
Dedicate 
This 
Thesis 
To My Parents 
who planted the seed, watched it ~row . . . 
.:\nd to you, dear GOD, for making this possible! 
MFS ! 
TJII JJIP7'RV~ 
iv 
Finally, the author thanks his sister, Carolina 
M. R. Sylvestri, for her invaluable assistance in the prep-
aration of this thesis. 
TABLE OF CONTEN'l'S 
LIST OF TABLES. 
LIS'r OP JnGURES • 
INTRODUCTION •.. . . . . . 
Factors Affecting Bioavailability . 
Compendia! Standards. . . . . . . . . . . 
Bioavailability Protocol ........ . 
The Need. to Establish the Bioavailability of 
Phen6barbital Tablets 
MATERIALS AND METHODS . . . . . 
o e e 0 e I 
Part I - Determination of Physical Properties 
Weight • . . . 
Hardness ~ . . 
Di.sintegration 
Dissolution. . . 
. . . 
. . . . 
Part II - Bioavailability Study 
. . . . . . . . 
Experimental Design~ . . 
Experimental Protocol .. 
·· The EMIT Assay .. System. . 
RESUI.'rS . • 
• • • • • 0 
DISCUSSIONS AND CONCLUSIONS . 
SUMMARY· • • . . . . ~ . 
BIBLIOGRAPHY. 
. . . . . . . 
APPENDIX. . • 
v 
. . . . . . . 
. . . . . . . . . . . 
. . . . . . 
. . . . . . . 
Page 
vi 
viii 
1 
5 
11 
13 
15 
19 
20 
20 
20 
21 
21 
25 
25 
25 
26 
32 
98 
104 
106 
110 
Table 
I 
II 
III. 
IV 
V. 
VI 
VII 
VIII 
IX 
X 
.XI 
XII 
XIII 
XIV 
LIST OF TABLES 
Experimental Code for Manufacture~s of 
· Phenobarbital Tablets,· USP, 100 mg, 
Employed in This Study .. 
Tablet Weight .in Milligrams for the 7 
Products • . . ·· . . . . . .· . . . 
Weight Variation in Percentage Difference 
for the 7 Products that·Meet USP XIX 
Requirements . . . . ·. . . . . . . . 
Tablet Hardness in Kiloponds for the 7 
Products. . . . . . . . . . . . . 
Disintegration Time in Minutes for the 
7 Products that Meet USP XIX Requirements 
Standard Curve Data for Phenobarbital in 
Simulated Gastric Fluid . . . 
Dissolution Data for Product A. 
Dissolution Data for Product B .. 
Dissolution Data for Product C. 
Dissolution Data for P~oduct D. 
Dissolution Data for Product E. 
Dissolution Data for Product F. . . . . 
Dissolution Data for Product G. 
. 
Summary of Physical Property Data for the 
'7 Products . . . . . . . . . . . 
. 
. 
XV Standard Curve Data for EMIT Phenobarbital 
Assay. 
:XVI. Serum Phenobarbital Concentration Levels for 
Product A. • . . . . . . • . . . . . 
XVII Serum Phenobarbital Concentration Levels for 
Ptoduct B. . . . . . . . . 
vi 
Page 
19 
33 
35 
37 
39 
41 
44 
47 
50 
53 
56 
59 
62 
66 
67. 
69 
71 
Table 
XVIII 
XIX 
LIST OF TABLES 
(continued) 
Serum Phenobarbital Concentration Levels 
for Product C. . . . . . . . . . . . . . 
Serum Phenobarbital Concentration Levels 
for Product D. . . . . . . . . • . . . 
XX Serum Phenobarbital Concentration Levels 
vii 
Page 
73 
75 
for Product E. . . . . . . . . . . . . . 77 
XXI 
XXII. 
XXIII 
·XXIV 
XXV 
XXVI 
XXVII 
XXVIII 
XXIX 
XXX 
Serum Phenobarbital Concentration Levels 
for Product F ............. . 
Sertim Phenobarbital Concentr~tion Levels 
for Product G. . . . . ~ . . . . . . . . 
Summary of the Bioavailability Data for 
the 7 Products . . . . . . . . . . . 
Statistical Analysis of Product A Bio~ 
~vailability . . ~ . . . . . . . . . 
Statistical Analysis of Product B Bio~ 
availability ........... . 
Statistical Analysis of Product D Bio~ 
availability . . . . . . . . . . . . 
Statistical Analysis of Product E Bio-
availability . . . . . . . . . . . . 
Statistical Analysis of Product F Bio-
availability ........... . 
Statistical Analysis of Product G Bio-
availability ........... . 
Correlation Data Profiles for the 7 
.Products. . ......... . 
.79 
81 
85 
86 
88 
90 
92 
94 
96 
103 
LIST OF FIGURES 
Figure P:ige 
1. Ultraviolet Scan of Phenobarbital in Simu..:. 
lated Gastric Fluid at a conentration of 
0.10 mgfml. . . . . . . . . . . . . . . 40 
2. Standard Curve for Phenobarbital in Simu-
lated Gastric Fluid . . . . . . . . . . 42 
3. Simulated Dissolution Strip-Chart Readout 43 
4. Mean Dissolution Profile Curve for Product A. 46 
5. Mean Dissolution Profile Curve for Product B. 49 
6. Mean Dissolution Profile Curve for Product c. 52 
7. Mean Dissolution Profile Curve for Product D .. 55 
. 8. Mean D1ssolution Profile Curve for Product E. 58 
9. Mean Dissolution Profile Curve for Product F. 61 
10. Mean Dissolution Profile Curve for Product G. 64 
11. Composite Mean Dissolution Profile Curves 65 
12. Standard Curve for the EMIT ·Phenobarbital· 
Assay . . . . . . . . . . . . . . . . . 68 
13. Mean Serum Concentration-Time Curve for 
Product A .. . . . . . .... . . . . . . . 70 
I 
14. Mean Serum Concentration --Time Curve for 
Product B 72 t . . . . . . . . . . . . . . . 
15. Mean Serum Concentration-Time Curve for 
Product c . . . . . . . . . . . . 74 
16. Mean Serum Concentration-Time Curve for 
Product D . . . . . . . . . . . . . . . 76 
viii 
LIST 01<' FIGURES 
(continued) 
ix 
Figure Page 
17. Mean Serum Concentration-Time Curve for 
Product E. • . . . . . . . . . . . . . . 78 
18. Mean Sertml Concentration-Time Curve for 
Product F. . . . ~ . . . . . . . . . . . 80 
19. 
20. 
21. 
Mean Serum Concentration-Time Curve for 
Product G . .... ~ .......... . 
Composite Mean Serum Concentration-Time 
Curves . . · . . . . . . . . . . . . . . . 
Composite Bar Graph of Mean Areas Under 
Serum Concentration-Time Curves. ~ . . . 
82 
83 
84 
INTRODUCTION 
The science of biopharmaceutics is concerned with 
the relationship of the physical and chemical properties of 
drugs and their dosage forms and the biological Bffects 
observed following the administration of the drug product 
(1). The science of pharmacokinetics deals with the study 
of the time course of absorption, distribution, m.etabolism 
and excretion of drugs in a biological system (2). There-
fore, it is through biopharmaceutical and pharmacokinetic 
research that the efficacy of all pharmaceutical dosage forms 
should be determined. When the biopharmaceutical and 
pharmacokinetic parameters of a drug have been fully charac-
terized, then the·availability of the drug in the biological 
system can be established. 
In the late 1960's, the Division of Medical Sciences, 
·National Academy of Sciences, National Research Council~ con-
ducted a Drug.Efficacy Study for the Food and Drug Adminis-
tration (FDA). This study originated from the Kefauver-
Harris Amendments of 1962 to the Food, Drug, and Cosmetic 
Act of 1938. The amendments applied to all drugs that had 
been introduced and marl(eted under the New Drug Applications 
(NDA's) approved·within the time period of 1938 to 1962 (3). 
The Food, Drug, and Cosmetic Act of 1938 required 
a producer of a new drug to substantiate the safety of the 
1 
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drug product· when .used as recormnended; however, .th,e intro-
duction of the Kefauver-Harris Amendments of 1962 consider~ 
ably s~rengthened this act. These amendments intensified 
the controls on quality, labeling, and safety, while adding 
a new.requirement that all NDA's should be able to present 
substantial evidence of the effectiveness of the drug product 
for its indicated use or uses (4). 
· The procedure used to determine the. efficacy of a 
drug included identification of the product, copies of the 
labeling, and a bibliography of publications substantiating 
the claims made for the drug. The manufacturers·were also 
requested to submit any unpublished in format ion ·fo further 
substantiate the claims made for the drug product (5,6) . 
. The conclusion of the Drug Efficacy Study resulted 
in a letter dated 24 January, 1969, soliciting comments from 
the 200 panel members and consultants of the Drug Efficacy 
Study. From these solicitations, the Policy Advising Com-
mittee of the Drug Efficacy Study reviewed the responses, and 
these wer~ incorporated as an appendix to. the final report (7). 
The views expressed by the partic.ipants were: 1) t.hat 
inadequate data were presented for the drug evaluations, 2) 
iden~ical drug products made by different manufacturers were 
not necessarily equivalent in their efficacy, 3) a similar 
drug evaluation study should be conducted on those drug. 
products introduced prior to 1938, and 4) that the need ex-
isted for a continual reView of the drug market (8). 
;'·. 
!: 
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Today, the issue of bibavailability1 is of paramount 
importance because it is of concern to every segment of our 
society. Bioavailability not only poses problems to health 
care-professionals, but also to government officials and, 
above all, to the people who are the ultimate recipients 
of medical care. 
The problem of bioinequivalence has made its presence 
known for approximately the last 20 years. It has only re-
cently come to the foreground because of the announcement from 
the Health, Education. and Welfare Department concerning the 
maximu~ allowable cost (MAC) policy for persons under the 
Medicaid and Medicare programs (9). MAC policy requires 
that the medical care recipients under such programs as 
Medicaid ahd Medicare who need a prescription drug·would re-
ceive the lowest priced generic drug product. Such·a policy 
overlooks the issue of bioavailability, and economics be-
comes the primary concern of providing effective medical care 
in terms of prescription drug products. 
Such economic concerns were the result of third par-
ties, including f~deral, state, and private agencies purchas-
ing the· drug products. Involvement by these third parties 
has placed an overemphasis on the selection of drug products 
on the basis of price alone (10). 
Bioavailability ·is a real issue as shown by a study 
1Definitions of terms peculiar to the area of bio-
pharmaceutics and pharmacokinetics used throughout this 
thesis are found in the appendix. 
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(11) conducted on 16 different lots of oxytetracycline cap-
sules, 250 mg, from 13 different suppliers, . ali of which had 
been certified by the FDA. Results from this study indi-
cated that all but one of the products tested had met the 
standard regulatory requirements. Further analysis of these 
produc.ts established that 7 out of the 16 lots produeed blood 
·levels below the minimum therapeutic level of 0.6 J..lgjml. It 
was observed that the lots which h~d the low serum levels 
• also had a slower dissoltttion rate in vitro. An additional 
study (12), involving all 11 manufacturers supplying the 
United S~ates market with oxytetracycline capsules, 250 mg, 
clearly revealed that chemical equivalents of oxytetracycline 
were not bioequivalent. 
In a crossover study (13), digoxin tablets, 0.5 mg, 
from different manufacturers were orally administered to 
normal human volunteer subjects. Marked differences in serum 
digoxin lev~ls were observed after dosing with these various 
products. In another ~tridy (14),· 2 diff~rent formulations 
.of tolbutamide, both generically equivalent in t~rms of chem-
.ical content and both meeting the specifications as set forth 
in the United States Pharmacopeia (USP), were found to be 
non-equivalent in terms of bioavailabilityor therapeutic 
effica6y. Results from a study (15) involving· single lots 
Of 14 different nitrofurantoin tablets which met the USP 
standards showed that 2 of the lots were significantly less 
bioavailable than the other products tested. 
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Factors Affec_ting Bioavailabil~ t~ 
Bioavailability is a complex problem due to the many 
variables associated with the development of drug dosage form 
design. The bioavailability of a drug product can be in-
fluenced by pharmaceutical formulation factors as well as 
by the physi6logical factors of the patient taking that drug 
product. 
The activity of the drug at its site of action in 
the body is related in a quantitative way to its concentra-
tion in the blood and in other physiological fluids and to 
the rate at which the body eliminates the drug. Factors 
such as protein binding, storage sites~ biotransformation, 
and the rate at which.the drug is made available to the 
blood andf6r other physiological fluids will also affect the 
activity of the drug. Therefore, for a drug to produce a 
pharmacological response, it must be absorbed in sufficient 
quantity and at an appropriate rate so that a minimum effec-
tive concentration can be ~stabli~hed at the site of action 
(16,, 17). 
The gastrointestinal barrier is a highly complex struc-
ture·co~posed of many chemical compounds, such as lipids, 
proteins, lipoproteins, and polysaccharides. This barrier 
is a semi-permeable membrane, permitting the passage of certain 
substances while retarding or preventing the passage of other 
substances. Since drugs are usually absorbed from the gastro-
intestinal tract by passive diffusion, the rate of absorption 
is then directly proportional to the concentration of the 
drug in the gastrointestinal fluids (16). 
6 
As an orally administered drug passes through the 
various regions of the gastrointestinal· t~act, it is subjected 
to many different environments with respect to pH, enzymes, 
and fluidity, in addition to the various anatomical regions 
that exhibit different surface properties (16,18). This is 
illustrated by the fact that the large surface·area of the 
small intestine is well suited to passively Rbsorbed drugs, 
as compared to the stomach and colon which constitute re-
gions of limited surface area (16). The varying pH range 
of the gastrointestinal tract and its contents infl~ence the 
am6unt, distribution, and absorption of a dissolved drug (19). 
Generally, differences in therapeutic efficacy runong 
drug products are most frequently due to differences in the 
rate at which the active ingredient becomes available for 
absorption. This variability can be attributed to differences 
in pharmaceutical formulations. Formulation variables can 
alter the onset, intensity, and duration of the desired 
. physiological/pharmacological response; in add it ion, the 
efficacy and the bioavailability may also be affected, and 
the incidence arid intensity of side effect~ and toxic · 
reactioris may be altered (20). 
' . 
Formulation variables affect drug absorption by 
either modifying the dissolution rate of the drug or by 
~hangi~i the rate of absorption of the drug across a biolog-
ical membrane (21). Drug availability can be controlled 
by altering the various pharmaceutical formulation factors 
affecting dissolution. Dissolution rate is described by 
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the Noyes-Whitney Law which defines the rate at which solids 
dissolve in their solutions. The law states that the rate 
of concentration change is at any given time interval 
directly· proportional to the difference between the con-
centration of ~ saturated solution and the concentration 
existing in the solution at that time (1,21,22). 
The following equation describes the law 
dW/dt = K·S(Cs - C) 
where dW/dt is the dissolution rate, S the surface area of 
the dissolving solid, C the c6ncentration of the drug in 
the dissolution medium, C the concentration of the drug in 
s 
the diffusion layer surrounding the solid substance and. 
thus representing a saturated solution, and K the dissolution 
rate constant (1,21). Therefore, by altering the physical 
characteristics, one can estimate the bioavailability of 
a drug by controlling the solubility of the drug by modify-
ing the environment in which the drug is to be dissolved. 
The dissolution rate of a drug is modified by alter-
ing the particle size of the drug used in a formulation. A 
reduction in particle size will increase the su~face area 
of .the drug particle, resulting in a greater availability 
of the drug in the physiological system. In some cases, 
however, reduction of particle size has caused too rapid a 
dissolution, resulting in a loss of availability of the drug 
because o{ malabsorption (21). 
The saturati6n solubility of a drug can be altered 
by chemically modifying the formulation and by modification 
8 
of the dissolution environment. The solubility of salts of 
weak acids or bases is altered by adjusting the pH. In-
creased availability has been demonstrated with an adjust-
ment of the pH in the immediate environment surrounding 
the drug by either increasing or decreasing the pH. These 2 
methods can be used: 1) buffering the drug by adding a 
solid basic substance to the formulation or 2) fashioning 
the drug into its sodium salt (21). 
Polymorphic structures of a subst~nce have different 
melting points~ molecular arrangements, and solubility 
characteristics exhibiting different stabilities and avail-
abilities when in solution. The crystal form with the 
lowest free energy is the most stable polymorph, while the 
form w~th the highest free energy is the most unstable. 
From a pharmaceutical viewpoint, the metastable polymorphs 
of a subst:u1ce are preferred. They exhibit greater solu-
bilities and dissolution rates compared to the stable forms 
of the same compound (23). 
Other physical properties of the active ingredient 
must be considered in pharmaceutical formulation. It has 
been sho~n that the amorphous forms of a dru~ are more 
soluble than crystalline forms .of the same drug, resulting 
in marked differences in the rate of a pharmacological 
1·esponse ( 24). 
Solvated and non-solvated forms of a drug must also 
be considered. It has been shown that drugs form solvent 
addition products called solvates. Solvated forms of a drug 
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exhibit differences compared to their anhydrcn3.s equivalents 
with respect to dissolutiQn rate and the drugs' availability 
(21,24). 
Adjuvants in pharmaceutical formul~tions can affect 
the dissolution rate of the active ingredient in a dosage 
form, even though an adjuvant has been defined as a sub-
stance &dded to a formulation.that is not intended for medic-
inal effect nor intended t6 alter or control drug availability. 
Adjuvants may be disintegrating agents, fillers, lubricants, 
binding agents, emulsifying agents, or suspending agents. 
It has been shown that an adjuvant increases the total 
solubility of the dosage form by influencing hydrogen ion 
concentration at the face of the barrier.immediately adjacent 
to the surface of the solid. This increase iri solubility· 
results in an increase in the rate of solution and there~ 
fore makes the drug more available (24). 
Anothe~ phenomenon associated with pharmaceutical 
formulation is adsorption. Adsorptiori occurs when the active 
ingredient in a dosage form adsorbs onto the surface of a 
solid adjuvant resulting in a decreased bioavailability of 
the drug. Complex· formation has also been observed between 
the active ingredient and adjuvants resulting in enhance-
ment or hindrance of the availability of the active ingredient 
because this phenomenon can lead to changes in the solu-
bility and absorbability of the active ingredient (24). 
Lubricating agents used in pharmaceutical formula-
tions are substances that a:re generally water insoluble and 
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water repellant. Such lubricating agents_decrease the dis-
solution rate of the active ingredients. This decrease in 
dissolution r~te is a result of inadequate c6ntact between 
the active ingredient and the physiological fluids~ How-
ever, a water soluble lubricant like sodium lauryl sulfate 
can significantly increase the bioavailability of drugs (24)~ 
The clinical efficacy.of a drug can be modified by 
the rate and extent of absorption of an active ingredient 
from a drug formulation as it enters into the systemic cir-
culation. Evidence has shown that the absorption character-
istics of a drug product, and the therapeutic performance of 
the drug is markedly affected by the substances and methods 
used in the manufacturing process (16). Consequently, phar-
maceutical drug formulations cannot be considered therapeu-
tically equivalent only because they contain the same amount 
of active ingredient or ingredients and comply with accepted 
official standards. Drug products exhibit differences in 
bioavailability, resulting in different clinical responses 
{21). 
'fhe bioavailability issue is a perplexing problem. 
In order to compare dosage forms of drug products, one must 
consider the following points: 1) characteristics of the 
pharmaceutical formulation, 2) manufacturing procedrires, 
and 3) possible interaction of other components in the 
formulation with the active constituent in the drug pro-
duct (25). 
11 
Compendia! Standa~ds 
It is generally accepted that compliance with com-
pendial standards assures chemical equivalency; however, 
such compliance does not assure therapeutic equivalency. 
Consequently, it is essential that additional standards 
and specifications be established to control the thera-
peutic equivalency of drug products (25). 
The Content Uniformity requirement is a means of 
demonstrating the uniformity of the content of the active 
drug substance or· substances in solid dosage forms. This 
requirement serves as a means of assurance that successive 
units from a given container will contain equal amounts of 
th~ drug. The Content Uniformity test is required for all 
tablets of the 50 mg size or smaller. However, tablets 
larger than the 50 mg size need not meet this requirement, 
because there seems to be little need to add this require-
ment to the testing of tablets that contain relatively 
little diluent or excipient and can therefore be controlled 
satisfactorily through the Weight Variation test. On the 
other ·hand, weight variation is not an indication of con-
~-
tent u~iformity when the drug substance comprises a rela-
tively minor portion of the tablet or when the tablet.is 
coated (26,27). 
Disintegration ~epresents an important character-
istic of tablet dosage forms and usually occurs before the 
active constituent of the tablet can dissolve and ulti-
mately be ab~orbed. The Tablet Disintegration test was 
~-
·, 
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the first attempt to establish an :lndieator for·the avail-
ability of a drug for absorption into the systemic cit·-
culation (25). The term disintegration, however, does· 
not imply complete solution of the tablet or its active 
constituent (28). 
This test has proven to be useful as a qualit~ con-
troi procedure for compressed tablets; however, it does 
have limitations. Passing the test ohly assures that the 
tablet has broken up into small particles ~ithin an estab-
lished period of time~ The Disintegration test does not 
-give assurance of a satisfactory rate of solution of the 
active medicament from the tablet. It becomes an important 
consideration if the drug has a low solubility: or is slowly 
.soluble~ The Disintegration test does not take into ac-
count the possibility of an interaction occurring between 
the tablet excipients and the active constituent, com-
plexing the .active drug, resulting in an inactive, insoluble 
drug-complex. It has been reported that a drug must be in 
solution before.it can be absorbed; consequently, a tablet 
rna~ prove ineffective from a clinical consideration, though 
it rnee~s the specifications of the Disintegration test. 
I 
'rhus, compliance with the requirements of the Disintegration 
test is not necessarily an indication of therapeutic effi~ 
cacy (25). Therefore, suitable dissolution char·acteristics 
are an important property of a satisfactory drug product (29). 
The Dissolution test is a quantitative method for 
determining the dissolution characteristics of a solid dosage 
i. 
~: 
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form. It is a method of deierminin~ the quantity of drug 
that dissolves within a designated time period in a specified 
volume of fluid in which the dosage form is immersed and 
agitated under carefully contr6lled conditions. 'I'his test 
permits the evaluation of the biological equivalency of chem-
ical equivalents, when correlation has been shown between 
in vitro dissolution rates and data obtained from normal human 
subjects through blood level or urinary excretion studies 
{25,30). 
Compressed tablets are the most widely used of all 
the dosage forms, and they present the most problems in re-
gard to the bioavailability of the active component. This 
is especially true for those compressed tablets that contain 
drugs with a low solubility, a low rate of solution, drugs 
which exhibit poor absorption characteristics, drugs which 
are·uustable in the gastrointestinal environm~nt or drugs 
that are used in large dosage (25). 
BioavailabiJ.ity Protocol· 
rrhese above considerations make it clear that experi-
mental data regarding bioavailability needs to be obtained 
for tablet dosage forms. Useful data can be obtained when 
" the e·xperimental design protocol follows certain criteria. 
Protocol usuall~ requires a crossover study utilizing 10-20 
normal healthy human adults ranging in age from 20-40 years 
who are within 10% of their ideal body weight. Individ-
uals with a history of gastrointestinal, liver, or kidney 
14 
disease or any other significant organ abnormality or 
disease and individuals who requi~e anj medication bn a daily 
regimen or who have a hypersensitivity to the drug being 
studied must be excluded from the protocol. All of the 
subjects must begiven physical examinations within 30 
days before the initiation of the study, and appropriate 
clinical pathological laboratory tests must be performed 
{31,32,33). 
Depending on the objective of the bioavailability 
study~ diet arid fluid intake may be controlled. At specified 
time intervals blood and/or urine samples are collected 
and analyzed quantitatively to determine the amount of 
active ingredient or ingredients present. The analytical 
data obtained is then evaluated for therapeutic levels of 
the active ing~edient or ingredients (31). 
The significance of a bioavailability study ~s 
established when a correlation is demonstrated between the 
blood levels achieved using a drug already shown to b~ 
clinically ~ffective and the drug product being tested (34). 
This type of relationship tendsto indicate that the drug 
produc~ being tested would be therapeutically .equivalent 
to the reference drug product (35). 
Bioa~ailability data is necessary for the estab-
lishment of therapeutic equivalency among drug products. 
Consequently, bioavailability data should be compiled for 
all drug products; particularly for those drug products 
most often prescribed. 
The Need to Establish the 
Bioavailability.of P~o­
barbital Tablets 
15 
Phenobarbital tablets have been listed among the 
top 5 generic products, by new prescription volume, for the 
last 4 years. In addition, phenobarbi~al tablets have also 
been the leadin~ drug product among the top 20 generic pro-
ducts by refill prescription volume over the last 4 years. 
Of the top 20 g~neric products by new and refill prescrip-
tion volume, phenobarbital products have ranked among the 
top 3 for the past 4 years. Furthermore, phenobarbital tab-
·lets have been listed among the top 4 drug products in a 
list of the average retail new prescription prices of the 
top 20 generic products in the last 4 years (36). 
From a physiochemical·basis,.the bioavail~bilit~ 
of phenobarbital tablets has been suspect. Phenobarbital 
is soluble"~ta the extent of 1 g in 1000 ml of water, which 
represents a value of 0.100% wfv. However, Sedam, Gennaro 
and Osol (37) showed that at 28° phenobarbital was soluble 
to the extent of 1 g in 783 ml of water, which repreients 
a value of 0.128% wfv. Similar studies have shown that at 
25°; phenobarbital exhibited solubilities of 0.109% wfv, 
0.120% ~fv, 0.110%.w/v, and 0.130% wfv (38,39,40,41). These 
differences in the solubility of phenobarbital at 25° may 
affect the dissolution iate of phenobarbital, the rate of 
absorption of phenobarbital into the systemic circulation, 
and ultimately the bioavailability of phenobarbital tablets. 
It has been reported that phenobarbital has exhibited 
lilUCJJI!it@&WWJZ&i&WZ.Z us a a 
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13 polymorphic forms (19,42,43). Clements and Stanski 
(43) demonstrated differences in the dissolution rates of 
4 polymorphic forms of phenobarbital. They showed that· 
Forms III and IV had faster dissolution rates than Form 
II and that Form XIII had a similar dissolution rate to 
that of Form II. The metastable forms of phenobarbital 
were found to dissolve at a faster rate than the stable 
form. This observation is expected because the free energy 
of the metastable polymorph exceeds that of the stable form. 
·Since the di~solution rate is rel~ted to the solubility as 
demonstrated by the Noyes-Whitney equation, the metastable 
form would thus be expected to show a faster rate of dis-
solution. Therefore, the dissolution rates of the poly-
morphic forms of phenobarbital have been us~d to determine 
the diffe~ences in the rate of absorption from the gastro-
intestinal tract and in the prediction of their bioavail-
ability when incorporated into pharmaceutical formulations. 
Jacob and Plein (44) demonstrated the need for de-
termining the bioavailability of phenobarbital tablets. In 
their study, the USP XVII Tablet Disintegration test was 
performed on 42 lots of phenobarbital tablets. Of the 42 
lots tested, 1 lot failed the test using the disks, whereas 
12 lots of tablets failed the test without the disks. How-
ever, the dissolution data in this study showed that 13 lots 
of tablets failed to release 100% of the phenobarbital into 
the simulated gastric fluid within 30 min. At the end of 
60 min, 3 lots out of the 13 lots of tablets did not release 
1.7 
50% of the drug. In fact, l manufacturer showed consider-
able tablet-to-tablet variation in dissolution rate. These 
same 13 lots were then subjected to the Dissolution test in 
an alkaline medium buffered at pH 9~5. In spite of the 
fact that phenobarbital is soluble at pH 9.5, 11 out of the 
13 lots of tablets did not release 100% of the phenobarbital 
·in 30 min. The differences observed in the dissolution rates 
of these various lots of commercial phenobarbital tablets 
were attributed to pharmaceutical formulation factors. 
Jacob and Plein (45) also demonstrated that phar-
maceutical formulation factors are of significant importance 
in altering the bioavailability of phenobarbital tablets. 
The data fromthis study showedthat an increase in binder 
concentration and hardness of compression resulted in a 
decrease in the dissolution rates of phenobarbital tablets. 
It was reported in a study by Solvang and Finholt 
(46) that the rate of release of phenobarbital from granules 
and tablets prepared with gelatin as a granulating agent 
was faster than the rate of dissolution of the pure drtig . 
. In addition, phenobarbital showed a hi~her rate of release 
from the tablets than from the granules. The slower rate of 
release of the phenobarbital from the granules was postu-
lated to be caused by the compression process which leads to 
deformatjon or crushing of the granules, increasing the 
spe~ific surface area of the granules and concomitantly 
increasing their rate of dissolution. This study demonstrated 
. ~· ' 
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the fact that the rate of dissolution of phenobarbital from 
tablets prepared with gelatin as.a granulating agent in-
creased with decreasing particle size of the drug. Further-
more, it also showed that phenobarbital tablets prepared with 
gelatin as a granulating agent dissolved much faster in 
human gastric juice th.an tablets prepared with other types 
of binding agents examined. The author$ found that gelatin 
makes the hydrophobic surface of the drug particles hydro-
philic, whereas other binders examined converted the drug 
into the less hydrophilic form or produced a complex re-
ducing the solubility of phenobarbital. The results obtained 
from this study reinforced the fact that pharmaceutical 
formulation variables are of extreme importance, for these 
variables not only alter the dissolution rate of phenobar-
bital tablets, but also ultimately affect the bioavailability 
of phenobarbital tablets. 
The incomplete data available on phenobarbital tab-
lets indicated the necessity for determining the physical 
properties and the bioavailability of these products. There-
fore, Phenobarbital Tablets, USP, 100 mg,.were obtained from 
7 manufacturers to characterize the physical properties of 
tablet weight, hardness, disintegration time, and dissolu-
tion rate; to determine the bioequivalency, bioavailability 
studies were conducted employing 5 normal, healthy human 
adult male subjects. 
t 
L 
MATERIALS AND METHODS 
Phenobarbital Tablets, USP, 100 mg, used throughout 
this study, were obtained from 7. manufacturers. Relevant 
data are presented in Table I. 
TABLE I 
Experimental Code for Manufacturers of 
Phenobarbital Tablets, USP, 100 mg, 
Employed in This Study 
Experimental 
Code L~ttera Manufacturer Control/Lot # 
A Eli Lilly & Co. 8KE19C 
~ndianapolis, IN 46206 
B Purepac Ph~rmaceutical Co. . 0128E4 
Division Elizabeth Laboratories 
Elizabeth, NJ 07207 
C Wyeth Laboratories, Inc. 1741821 
Philad~lphia, PA 19101 
D 
E 
F 
G 
Philips Roxane Laboratories, Inc. 
Columbus, OH 43216 
Vangard Labs 
Division of MWM Corp. 
Glasgow, KY 42141 
Kasar Laboratories 
Niles, IL 60658 
Parke-Davis & Co. 
Detroit, MI 48232 
750899 
4910 
1088085 
SB544 
aSubsequent tables, figures, and discussions are 
keyed to the Experimental Code Letters in Table I. 
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Determination of Physical Properties 
· We"i·ght 
The weight o;f 20.individual whole tablets of the 
same batch from each manufacturer were determined using an 
analytical balance, their weights recorded in milligrams 
and mean weight, and standard deviation calculated. ~he 
tablet weight data are presented in Table II (~. 33). 
These weight determinations were tested by the USP 
XIX Weight Variation test for uncoated tablets (47). This 
test provides limits for permissible variations in weights 
of iridividual dosage units, e~pressed in terms of the per-
centa.ge difference from the mean weight of a sample. · The· 
resUlts from the Weight Variation tests are presented ·in 
Table III (p. 35). 
Hardness 
The hardness of 20 individual whole tablets of the 
same batch from each manufacturer were determined by using 
the.Schleuniger Tablet Hardness Tester, 1 an electrohically 
! 
calibrated instrument operating on the counter-weight 
principle. The hardness for each tablet was recorded in 
kiloponds (kp) and the mean hardness and standard deviation 
1Rr. K. Schleuniger & Co., Universit~tstrasse 87, 
CH-8033 Zurich. 
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calculated. These tablet hardness determinations are pre-
sented in Table IV (p. 37). 
Disintegration 
The Disintegration test as prescribed in the USP 
XIX for uncoated tablets (48) was used on the tablets from 
each manufacturer. The disintegration times were recorded 
in minutes. The results from the Disintegration tests are 
presented in Table V (p. 39). 
Dissolution 
Preliminary Experiments - If a 100 mg phenobarbital 
tablet were to dissolve completely in a 1000 ml of simulated 
gastric fluid, a maximum phenobarbital concentration of 0.10 
mgjml would be obtained. Therefore, a solution of this 
above concentration was accurately prepared and scanned in 
2 an ultraviolet-visible scanning spectrophotometer. The 
scan obtained is shown in Fig. 1 (p. 40). It was obvious 
that the maximum absorbance was between a wavelength of 
200-228 nm, and that the absorbance was g~eater than 1.5 
{beyond the available scale of the chart range). Since an 
,, 
absorbance greater.than 1.0 can alter the sensitivity of 
spectrophotometers operating in the ultraviolet region, it 
was then decided to see if an ascending shoulde~ reading 
could he employed to analyze the phenobarbital tablets in 
later analyses. Upon further evaluation of the scan it was 
2
Model 202, Perkin-Elmer, Norwalk, CT 06856. 
\ 
l 
' ; 
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noticed that an absorbance (A) of approximately 0.67 was. 
obtained on the asce~ding shoulder of the scan at a wave-
length (A) of 240 .nm (see Fig. 1, p. 40). With this in-
formation, it was then decided to see if Beer's Law applied 
at this wavelength. Solutions of known concentrations of 
phenobarbital were prepared and their absorbances recorded 
at 240 nm (Table VI, p. 41). It was observed that Beer's 
Law was substantiated at this. wavelength as demonstrated 
by the line~rity of the standard curve (Fig. 2, p. 42). 
Therefore, ·in all later experiments, absorbances were re-
corded at 240 nm .. 
Standard Curve - The standard curve was prepared 
by making solutions of different known concentrations of 
phenobarbital using simulated gastric fl~id as the solvent·. 
A stock solution of 0.10 mgfml phenobarbital 3 was accurately· 
prepared. The following concentrations were prepared using 
the stock solution: 0 .. 01, 0.02, 0.03, 0.04, 0.05, 0~06, 
0.07, 0.08, and 0.09 mgfml. The absorbances for these var-
ious solutions were determined at 240 nm with the slit pro-. 
4 gram selector of the Beckman Spectrophotometric System in 
the normal positiol:J.. 
Method of Analysis - The Dissolution tests were 
performed by using the Beckman Spectrophotometric System, 
3Lot # SVY, Mallinckrodt Chemical Works, St. Louis, 
MO 63147. 
4 Model 25-7, Beckman Scientific Instruments, Fuller-
ton, CA 92634. 
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an analytical instrument specifically designed for tablet 
dissolution testing. This system is outfitted with a water 
bath for controlling the temperature within the vessels 
containing the dissolution fluid. Within and upon the 
water bath rests the multiple spindle and dissolution 
vessel apparattis. The multiple spindle drive unit provides 
for 6 tablet basket assemblies to be in operation simulta-
neously. thus allowing all 6 tests to be accomplished at 
one time. This system contains a multichannel pump which 
allows solution from each of the 6 vessel~ to be ,con-
tinously sampled to a· series of flow cells contained with-
in an automatic sample changer for spectrophotometric read-
ings. The automatic sample changer contains a temperature 
control device that allows the samples in the flow cells to 
be maintained at the same temperature as is the fluid in 
the ·dissolution vessels. The sample changer accommodates 
-7 cells, permitting continuous monitoring of the 6 tablet 
dissolution vessels plus an additional cell for a blank or 
for a theoretical concentration standard, thus allowing 
the results to be recorded on a strip-chart representing 
sample,absorbance or concentration (49). 
The Dissolution tests were run at 37° + 0.5° in a 
1000 ml of simulated gastric fluid (pH l. 2) which is pre-
pared by mixing 7.0 ml of concentrated HC1 5 with sufficient 
5Lot # WCLL, Mallinckrodt Chemical Works, St. Louis, 
MO 63147. 
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distilled, deionized water to make 1000 H1.1.. The spindle 
basket assembly was rota ted at 50 rpm. 'I'he pump, which 
continuously circulated the samples from the dissolution 
vessels through the flow cells and back again, was set for 
a flow rate of 2.5 ml/min. The concentrations of the sam-
pies were determined at 240 nm and directly recorded on 
the strip-chart (see Fig. 3, p. 43), moving at a speed of 
0.5 in/min. The slit selector was programmed at normal 
position with reference to a theoretical concentration 
standard of 0.10 mgfml. The readings were taken at 5 miri 
intervals during a period of 90 min with a dwell time of 
10 sec for each sample. 
In order to prevent tablet fragments from passing 
into the flo~ cells, each dissolution vess~l was fitted 
with a cellulose_ acetate filter with a pore size of 3 11 
in diameter. 
The dissolution data obtained from the strip-chart 
readouts are ·presented in Tables VII-XIII (pp. 44, 47, 50, 
53, 56, 59, 62). The mean dissolution profile curves are 
illustrated in Figs. 4-10 (pp. 46, 49, 52, 55, 58, 61, 64). 
A composite graph of the mean dissol~tion profile curv~s 
for the 7 products tested in _this study is shown in Fig. 11 
(p. 65). A summary of the results of the physical property 
data obtained is presented.in Table XIV (p. 66). 
-~ 
,, 
1 
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Part II 
Bioavailability Study 
To determine the bioequivalency of the various 
phenobarbital tablets, the following study was conducted. 
Experimental Desig~ 
An incompletely randomized crossover study was em-
played to compare the bioavailability. 
Experimental Protocol 
In this study, 5 normal, healthy human adult male 
subj ects6 v,rere employed: mean age 23.6 years (range 21-28 
y.ears), mean weight 78.4 kg (range 61-94 kg), and a mean 
height 183 em (range 173-193 em). Prior to the study, 
each subject 0is given a gene~al ph~sical examination and 
urine analysis7 and complete blood chemistry analysis 
(~MA 12/60). 8 The subjects were instructed not to ingest 
any drugs or alcohol for 48 hr prior to commencing the 
study and also·to abstain from ingesting any other drugs 
or alcohol throughout the duration of the study. 
6 Recruited from the student body of the University 
of the Paci.fic School of Pharmacy, Stockton, CA. 95211. 
7univ~rsity of the Pacific Cowell Health Center, 
Stockton, CA 95211. 
8
spencer Laboratories, 438 McCloud, P. 0. Box 
4488, Stockton, CA 95204. 
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The subjects were divided into 2 groups: Group A, 
2 subjects and Group B, 3 subjects. A single 100 mg pheno-
barbital tablet was orally administered with 240 m1 of water. 
T.he subjects were instructed to fast from the prior evening 
meal until 2 hr after ingesting the tablet. Different pro-
ducts were given to each group; the subjects in each group 
received the same products with a 6 day lapse between the 
administration of the various products. This procedure was 
repeated every we.ek for 7 consecutive weeks until both groups 
had received the phenobarbital t·ablets from each manufac-
turer. 
Blood samples were drawn by the fingertip method 
at intervals of 0.5, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0 and 
64.0 hr post-dosing. The samples were coll~cted in 6 
heparinized microcapillary tubes, centrifuged and refrig-
erated until the serum samples could be assayed by the 
( 
"Enzyme Multiple Immuno~ssay Technique"(EMIT)9 for pheno-
barbital content. 
The EMIT As~ay System 
Principle - The EMIT assay procedure is a homo-
geneous 'enzy1ne immu~oassay technique used for the micro-
analysis of specific compounds in biological fluids. 
----------·-------
9
"El\!IT" is a registered trademark of the Syva Corp., 
Palo Alto, CA 94304. 
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To perform the EMIT Phenobarbital Assay th~ fol-
lowing are required: 
1) the EMIT Phenobarbital Assa~ Kit which consist 
of: 
a. Reagent A (lyophilized antibody/substrate) 
contains antibodies made igainst a pheno-
barbital derivative. The antibodies are 
formed by chemically coupling the drug to 
a macromolecular carrier and immunizing · · 
sheep or goats with the resulting antigeri. 
The antibody/substrate preparation when re-
~onstituted contains a standardized prepara-
tion of the immunized sheep or goat gamma 
globulin, the enzyme substrate g1ucose-6-
phosphate (EC 1.1.1.49), and nicotinamide 
adenine diriucleotide, and preservatives in 
0.055M Tris HC1 buffer at pH 5.0. 
b. Reagent B (lyophilized enzyme) is prepared 
by chemically coupling phenobarbital to 
glucose-6-phosphate dehydrogenase. The 
reagent when Teconstituted contains the 
enzyme-labeled ph~nobarbital and preserva-
tives in 0.055M Tris HCl buffer at pH 7.9 
and has been standardized to match Reagent 
. A~ 
c. Buffer concentrate containing a surfactant 
wh,ich upon reconstitution results in a 
0.~55M Tris HCl pH 7.9 buffer solution.· 
2) the EMIT Drug Calibrators consist of a set of 6 
vials of lyophilized serum base preparations. 
3) the EMIT Control is a vial of lyophilized base 
preparation. 
· This assay- procedure requires a drug to be· labeled 
to an enzyme. When the enzyme-labeled drug becomes bound 
to an antibody against the drug, the activity of the enzyme 
is reduc.:::d. Free drug in a sample competes with ·the en2~ym<::-
labeled drug for the antibody and thereby decreases the 
antibody-induced inactivation of the enzyme. Enzyme activity 
correlates with the concentration of free drug introduced. 
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In the reaction of enzyme with the substrate, NAD+ is con~ 
verted to·NADH and the 6hanie in concentration of NAD+ is 
spectrophotometrically measured (50). 
In ~n actual assay procedure, controlled amountB oj 
antibody are added to a specimen. If the specimen contains 
phenobarbita1, it and the antibody bind to one another. Since 
the antibody is present in excess, the concentration of un-
bound antibody is directly related to the original concentra-
tion of the phenobarbital. When the drugjenzyme complex is 
then added, the degree of inactivation of the enzyme is direct-
ly related to the concentration of thri unbound antibody (50). 
Instrumentation - The instrumentation recommended 
and used to perform the assays consisted of: 1) a pipettorf 
dilutor, 10 for accurate sampling and diluting; and 2) a micro-
sample spectrophotometer11 equipped with a therm~lly regu-
1 t d fl 11 12 h · h · t d t t · 1 · t . 13 . a·e ow ce , w 1c 1s connec e o a 1mer pr1n er 
with memory .function and the capability of automatically 
timing 2 absorbance readings 80 sec apart and printing out 
the change in absorbance between the 2 readings (51, 52 ,.53). 
Assay Procedure - Using the pipettorfdilutor, 50 pl 
of standard or unknown serum sa~ple is-diluted with 250 pl 
10 . . 
· Model 1000; Syva Corp. , Palo Alto, CA 94304. 
11Mpdel 300-N, Gilford Instrument Laboratories Inc., 
Oberlin, OH 44074. 
12Model 3017, Gilford Instrument Laboratories Inc., 
Oberlin, OH 44074. 
13 . Model 2400, Syva Corp., Palo Alto, CA 94304 . 
. - ·-- - ----
- --- - --- ---
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of buffer solution in a l ml disposable beaker. A 50 ~~ 
sample of this dilution is transferred into a second 1 ml 
disposable beaker. To this second beaker is added 50 pl of 
Reagent A plus 250 pl of buffer, ·followed by 50 pl of 
Reagent B plus 250 ~1 of buffer (50,51). 
The assay mixture contained .in the second beaker 
is aspirated ·into the spectiophotometer flow cell. The 2 
absorbance readings are made at a wavelength of 340 nm: 
the initial reading after a 15 sec delay for thermal equi-
libration at 30°,and the final reading at 95 sec. The in-
dividual readings and the differences between them over 
the 80 sec time interval are automatically printed out 
(50, 51). 
Standard Curve - The standard curve is prepared by 
using the EMIT Calibrators. The calibrators consist of a 
set of 6 vials of lyophilized serum preparations containing 
precise amounts of phenobarbital that serve as standards 
to be used in the preparation of the standard curve. 
The vials were prepared and reconstituted according 
to instructions in the package insert. The reconstituted 
solutions contained the following concentrations of phenobar-
bital: 0 Pg/ml (Negat~ve Calibrator), 5.0, 10.0, 20.0, 
40.0 ind 80.0 Pg/ml. These concentrations as supplied by 
the nianufacturer should be used directly for assay of usual 
therapeutic levels of phenobarbital. How~ver, the levels 
of phenobarbital obtained with tbe doses given to the subjects 
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in this study were below those obtained in usual therapy. 
Therefore, to prepare the standard_ curve, the contents of 
the vials including the Negative Calibrator were further 
diluted 10 fold with distilled water,.the final concentra-
tions being 0, 0.5, 1.0, 2.0, 4.0 and 8.0 pgjml. 
The standard curve was.obtained by plotting the 
difference,. AA-~A for each c~librator, against the respec-
o 
tive concent~ation of the calibrator. The D.A represents the 
calibrator absorbance at each concentration. The AA repre-
o 
sents the Negative Calibrator absorbance. 'l'hese D.A-D.A 
0 
values are presented in Table XV (p. 67). EMIT graph paper, 
a modified legit function paper, produces a linear curve 
(50). 'l""'he standard curve is illustrated in Fig. 12 (p. 68). · 
Analysis of Subject Serum Samples - The EMIT Con-
trol serves as a check when measuring subject serum pheno-
barbital levels, since it contains precise amounts of pheno~ 
barbit~l and 4 other antiepileptic drugs in lyophilized 
serum. The control was diluted 10 fold with distilled 
water, resulting in a concentration 3.0 ~g/ml. 
The serum phenobarbital concentration levels obtained 
are presented in Tables XVI-XXII (pp. 69, 71, 73, 75, 77, 79, 
I 
81). The mean serum concentration - time curves are illus-
trated in Figs. 13-19 (pp. 70, 72, 74, 76, 78, 80, 82). A 
composite graph of the mean serum concentration - time curves 
for the 7 products tested in this study is shown in Fig. 20 
(p. 83). Fig. 21 (p. 84) represents a composite bar graph 
of the mean areas under the serum concentration - time curves 
-· - --------
-------- --- ------- --
- ---~- ----
,, 
' 
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for the 7 products. A sunm1ary o:f the rE:sults of the bio-
availability data obtained is presented in Table XXIII 
(p. 85). Statistical analyses of product bioavailability 
are presented in Tables XXIV-XXIX (pp. 86-97). 
The areas under the serum concentration - time 
curves were· obtained by using the "'I'rapezoidal Rule" (54) 
for observations over a period of 0 to 64 hr. Since these 
areas indicate the relative amount of phenobarbital absorbed 
in the physiological system, they also are estimates of the 
bioavailability of the drug from the various products. The 
significance of the bioavailability determinations for all 
products, was determined by "Analysis of Variance" (55). 
RESULTS 
Verification of experimental methods, the results 
of the physical property data, and the results of the bio-
availability data obtained throughout this project have been 
compiled and are presented in the tables and figures that 
follow. 
of: 
of: 
The results of the physical property data consist 
1) Tablet Weights 
2) Tablet Weight Variation Determinations 
3) Tablet Hardness 
4) Disintegration Times 
5) Dissolution Characteristics 
The results from the bioavailability data consist 
1) Serum Phenobarbital Concentration Levels 
2) Peak Serum Phenobarbital Concentration Levels 
3) Time of Peak Serum Phenobarbital Concentration 
Levels 
4) Areas Under the Serum Concentration-Time Curves 
5) Statistical Analyses of Product Bioavailability 
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TABLE II 
Tablet Weight in Milligrams for the 7 Products 
Tablet Weight, mg 
Sample 
Number tProduct A Product B Product C Pi~oduct D Product E Product F Product G 
1 178.5 > 301.4 345.2 175.0 197.1 185.4 227.5 . 
2 176.2 304.8 351.1 173.3 205.1 177.9 227.7 
3 177.9 292.7 353.2• 175.2 204.6 179.5 229.5 
4 174.9 305.8 347.8 184.3 203.2 178.1 229.8 
5 178.8 298.8 352.8 178.8 206.2 181.3 228.5 
6 177.6 302.1 347.8 178.8 200.0 179.5 227.5 
7 180.0 297.3 345.5 173.6 210.0 180.0 . 228.7 
8 179.8 296.0 350.4 174.0 209.0 180.6 227.0 
9 180.0 295.3 350.7 177.9 206.3 176.3 230.4 
10 177.3 299.2 348.6 172.9 209.8 175.4 229.2 
11 178.4 303.5 346.8 181.0 211.4 177.3 228.8 
12 176.0 301.0 350. o. 175.7 205.6 179.5 231.3 
13 179.9 307.4 354.9 173.1 205.5 184.3 231.4 w w 
........ _., ... ,.,, .. ;;;:-,..,... ...... r ... .,..,..,~~ 
' 
Sarnp1e 
Table II 
(continued) 
Tablet Weight; mg 
Number Product A Product B Product C ·Product D Product E Product.F Product G 
14 
15 
16 
17 
18 
19 
20 
Mean + 
S.D. 
180.0 307.1 
178.7 300.0 
177.7 297.0 
181.5 302.0 
176.6 296.8 
179.0 303.0 
181.7 297.2 
178. 5+1. 8 300.4+4.1 
350.3 171.4' 
350.0 ' 181.1 
348.3 173.8 
346.5 179.2 
346.3 182.2 
347.7 165.8 
347.9 177~6 
349.1+2.6 176.2+4.3 
.f 
209.3 178.8 228.1 
212.2 180.6 228.0 
207.2 182.6 227.2 
202:6 180.8 227.7 
206.5 181.6 229.7 
206.8 180.4 229.8 
204.4 186.3 229.1 
206.2+3.7 180.3+2.8 228. 9+1. 3 
': ~::: .. 
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~ 
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TABLE III 
Weight Var-iation in Percentage Difference for the 7 Products 
that Meet USP XIX Requirements 
Sample Weight Variation.Difference~ % 
Number Product A Product B Product C Product D Product E Product F Product G 
l 0 0.3 1.1 0.7 4.4 2.8 0~.6 
2 1.3 1.5 0.6 1.7 0.5 1.3 0.4 
3 0.3 2.6 1.2 0.6 0.8 0.4 0.3 
4 2.0 1.8 0.4 4.6 1."5 1.2 0.4 
5 0.2 0.5 Ll 1.5 0 0.6 0.2 
6 0.5 ' 0. 6 0.4 1.5 3.0 0.4 0.6 
7 0.8 1.0 1.0 1.5 1. 8 . 0.2 0.1 
8 0.7 1.5 0.4 1.3 1.·4 0.2 0.8 
I 
! 
9 0.8 .1.7 0.5 i 1.0 0.1 2.2 0.7 
10 ·0.7 0.4 0.1 1.9 1.8 2.7 0.1 
11 0.1 1.0 0.7 2.7 2.5 1.7 0 
12 1.4 0.2 0.3 0.3 0.3 0.4 .1.1 
c.u, 
13 0.8 2.3 1.7 1.8 0.3· 2.2 1.1 CJ, 
.14 0.8 2.3 0.3 2.7 ·1. 5 0.9 0.4 
.--....-~...:--······· ......... ~-~ ... - ..... ....__ •. ..,.,.,.._~-.:-.-................ ,._,._......_.~~-~~?]K~~i..~·...:;~.;:~ ... o<l..\.:''·.t!'~-~~···,.<.:·'·""J.·..,~~'lo·'<l-~~j~ .... -· 
Satnple 
Number Product. A Product B 
15 0.1 . 0.1 
16 0.5 1.1 
17 1.7 0~5 
18 1.1 1.2 
19 0.3 0.9 
20 L8 1.1 
. ,,.,,~~j~'\'.'~k; : 'i[:t:··'';;;i,i; '; ''\'!'• •:ff~~~~!· 
TABLE III 
(continued) 
Weight Variation Difference, % 
Product C Product D ·Product E Product F 
0.3 2.8 3.0 0.2 
0.2 1.4 0.5 1.3 
0.7 1.7 1.8 0.3 
0.8 3.4 0.2 0~7 
0.4 6.0 0.3 0.1 
0.3 0.8 0.9 3.3 
Product G 
0.4 
0.7 
0.5 
0.4 
0.4 
0.1 
·-. .. 
w 
.0':1 

~----~~~~~~~~~--~~= 
TABLE IV 
(continued) 
-'---·--·-----·---~---· 
. a Tablet Hardness, kp 
Sample 
·Number Product A Product B Product C Product D .Product E Product F Product G 
14 3.5 3.5 10.9 4.6 4.0 6.5 9.7 
15 3.4 2.6 9.1 4.5 3.4 6.9 8.4 
16 3.8 3.7 9.1 4.1 4.4 6.8 8.1 
17 3. 8. 3.6 10.8 3.7 2. 8, 6.3 7.1 
18 . 3.1 3.4 9.5 4.4 4.2 7.5 9.6 
19 3.6 3.8 10.6 5.5 4. 8. 7.3 9.3 
20 2.8 4.0 10.6 5 .0. 4.6 7.7 10.0 
Mean+ 3.5 + 0.4 3.5 + 0.4 10.3 +0.8 4.9 + 0.9 -4.1:+ 0.6 6.9-+ 0.6 9.1 + 0.9 
S.D~ 
aA Kilopond is defined as gn x (I· kg), where g =Acceleration due to 
gravity = 9.806 mjs2. · n 
··.' 
w 
/00 
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Product 
A 
I 
I B, 
c 
D 
E 
F 
G 
,~,~-~---~~-----------
TABLE V 
· Disintegration Time in Minutes· for the 
7 Products that Meet USP XIX Requirement 
~isintegration Time) min 
11.43 
1.47 
1.03 
4.05 
3.68 
11.93 
0.73 
w 
(,0 
~-__L....-~-_._-=---=-----=-----
0.0 
0.2 
0.4 
Q) 
o0.6 
c 
0 
..0 
'-~0.8 
.0 
c::( 
1.0 
L2 
1.4 
200 250 300 
Wavelength, n m 
350 
Figure 1. Ultraviolet Scan of Phenobarbital in Simulated Gastric Fluid at .a 
concentration of 0.10 mg/ml. 
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-:.,....., ..... _,,., ...... , ... ~---.-~."i':t:il" 
,._:.._---..,.....-'--------~----~---·" =-------~--~=· O•·C"''""''"'~'~~=~ 
Phenobarbital 
in Solution, 
mg/ml 
in Simulated 
Gastric Fluid 
0.01 
0.02 
0.03 
0.04 
0.05 
0.06 
0.07 
0.08 
0.09 
0.10 
TABLE VI 
Standard Cu~ve Data for Phenobarbital 
in Simulated Gastric Fluid. 
Absorbance at 240 nm 
Trial I Trj_al II Triz.l III 
0.072 0.070 0.070 
0.138 0.140 0.140 
. 0. 204 0.201 ·o.2o3 
0.270 0.271 0.270 
0.335 0.335 0.334 
0.403 0.402 0.403 
0.470 0.469 0.470 
0.538 0.536 0.538 
! 
0.603 0.601 0.603 
0.672 0.677 0.676 
,,, ________________ _ 
Mean + S.D. 
0.071 + 0.0012 
0.139 + 0.0012 
0.203 + 0.0015 
. -
0.270 + 0.00058 
0.335 + 0.00058 
0.403 + 0.00058 
0.470 + 0.00058 
0.537 + 0.0012 
0.602 + 0.0012 
0.675 + 0.0026 
~ 
1-' 
j 
I 
OJO 
"'0 0.08 
~-· 
-E 
' Ol E 0.02 
o.oo ...,._..==-=-+==--t----=-t---'"1-------t----t-~ 
0 0.20 0.40 0.60 : 
Absorbance at 240 nm 
·}'igure 2. Standard Curve for Pheno})~rbita1 _in Simulated-
Gastric FLuid. 
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Figure 3. Simulated Dissolution Strip-Chart Readout: 
' . . 
aLines 1 through 6 represertt :fl~w cells 1 through 6 a~d indicate dissolution 
vessels 1 through 6 containing dissolved amounts of phenobarbital from th~ Phenobarbital 
Products tested. · I · 
- ; I • 
bLine 7 represents :flow cell 7 ~hich contains the thebretical maximum pheno-
barbital concentration of 0.10 mgfmlp against which the disso!l.ved amounts of pheno- ~ 
barbital in flow cells 1 through 6 were measured and then rechrded. w 
I 
J 
TABLE VII 
Dissolution Data for Product A 
Di::;solution Phenobarbital in Solution, mg/1000 mla 
Sampling 
Time,. Min Test l Test 2 Test 3 Test 4 Test 5 
5 0 1.5 4.5 1Q5 0 
10 22.5 24.5 27.5 23.0 18.0 
15. 41.5 43.0 45.0 41.0 36.0 
20 53.0 53.5 54.5 52.5 47.0 
25 61.0 60.5 62.5 .. 60.5 54.0 
30 "66. 5 66.5 .67.0 65.0 59.0 
35 71.0 71.0· 71.5" 69.0 63.5 
40 74.0 74.5 75.0 72.0 67.0 
45 77.0 77 .. 5 78.0 •75.0 69.5 
50 78.5 79.5 80.0 77.0 72.0 
55 8LO 81.5 . 81.5 79.0 74.0 
60 82.0 ·s3.o 83.5 . f 81.0 76.0 
; 
65 83.0 83.5 84.0 81.5 77.0 
...... 
·-~~- ..... ··' ,;· . :· ~"'' .·\:. ···: ... _ . .,_ ,..,_ •. ,·<'"'.~ t ·'h--·. ~ .i,::~~ :.:.,~-::~ ,:...,~.:: ·:..:~-...:.:.~~.c.:.·~~~z.:·'"·~:"''·~-.... ~.:"fl'-:,. · · ·:::---. 
=-= II I 
I 
·r . 
TE!St 6 
!I_ 
Mean + S.D. 
1.5 1.5 + 1.6 
I . -
214.5 23.3 + 3~.1 
42- 0 41.4 + 3.0 
I • 
52.3 + 2.7 513.0 
610.0 59. 8. + 3. 0 
65.0 + 3.0 615.5 
710.5 69.4 + 3.0 
7·r .0 . 72.8 + 3 0 0 
71~ 5 75.6 + 3.2 ,. 
79.0 77.7 + 3.0 
I -81.0 79.7 + 2.9 
I -
8:~. 5 81.3 + 2.8 
I 
- . 
8:3.5 82.1 + 2.6. 
I 
-
I 
~ 
~ 
i 
I 
I 
l 
~ 
Dissolution 
Sampling 
Time, Min Test·l 
70 83.5 
75 85.0 
80 86.0 
85 86.5 
90 87.0 
TABLE VII 
(continued) 
. \ 
~henobarbital in Solution, mg/1000 ml, 
Test 2 Test 3 · Test 4 Test 5 fest 6 
84.0 85.5 83.0 78.5 85.0 
85.5 86.0 84.0 80.0 85.5 
86.0 87.0 85.0 80.5 86.5 
87.0 87.5 86.0 82.0 87.5 
87.5 88.0 87.0 82.5 88.0 
Mean + S.D. 
83.3 + 2.5 
84.3 + 2.2 
85.2 + 2.4 
86.1 + 2.1 
86.7 + 2.1 
aAmount of phenobarbital in solution~ mg/1000 ml iniSimulated 
Gastric Fluid as recorded on the strip-chart readout. 
! 
! 
~ ..,:';;.;::,.;;.:... , ... ~;'··. :;,t>o~'::¥. f'~~;,_;~t;·""t~·~:_,i;;~'t£~~~~;,.~~i;i;~~R(,~~~~~~1;;),~:li>~~.;>t<.;~~"#~l"-""""'.,.i...,..,.,....... .. ,.,,,. .. =..,_..•~~· ~· ---·· --~-
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·Figure 4. Mean Dissolution Profile Curve for Product A . 
..,.,_, ___ _ 
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TABLE VIII 
Dissolution Data for Product B 
1. 
Dissolution Phenobarbital in Solution 1 mg/1000 mla[ 
Sampling I 
'Time, min Test 1 Test 2 Test 3 Test 4 Test 5 TE:!St 6 Mean + S.D. 
I 
5 19.0 25.5 19.0 7.0 19.5 '16. 5 16.1 + 7.6 
10 46.0 52.0 45.0 33o5 54.0 38 0 44.8 + 7.9 
I 0 
15 58o0 64.0 57o0 58o0 70.0 ti6. 5 60.6 + 5.4 
I 
70.2 + 4.9 20 67o0 72.5 65.0 70.5 78.5 1t7. 5 
25 74.5 78.5 71.0 77.5 83.5 !ii6. 0 .76 .8 + 4 0 2 
30 80.5 84.0 75.5 82.0 87.0 812.5 81.9 + 3.8 
·35' 84.5 88.5 79.5 85.0 90.0 817.0 85.8+ 3.7 
40 '86. 5 90·. 0 82.5 88.0 92.0 911.0 88.3 + 3.5 
45 88.5 92.0 85.5 89.5 ·92.5 9\3.0 90.2 + 2~9 
' -
50 90.0 93.5 87.5 91.5 93.5 914.5 91.8 + 2.6 
55 91.0 94.5 90.0 92~5 94.5 915.5 93.0 + 2.2 
60 91.5 95.5 90.5 f '93. 5 95.0 91(3·. 5 93.8 + 2.4 
I 
65 92.0 95.5 92.0 i. 94.5 95.5 9'7 5 '94.5 +' 2.2 
I . 
,.·.-: .. ,,·: ... · ····-.: ... :; ~-· '€"'··"'" .): ·;~ -,•··; '.,.. ~:; ... >~.;.·::t·:_i~Z;~~~.;.,;~~:_t~~-;~:)~j~~~ti~~~[t~~~~ .. :,~~~~~"fij:~i-~~-i!lr;'s.S:::.+:;j;..r..::~·~~~~:~.+'""'~~..m~~---·-· -·· --~-· 
~ 
~ 
:· 
Dissolution 
Sampling 
Time, min 
70 
75 
80 
85 
90 
TABLE VIII 
(continued) 
Phenobarbital in Solution, mg/1000 mla 
Test 1 Test 2 Test ·3 . Test 4 Test 5 
92.5 97.0 92 0 5, 95.5 96.0 
. 93.0 98.0 93.0 96.0 96.0 
93.0 98.0 93.5 96.5 96.5 . 
93.0 99.0 94.0 97.0 97.0 
93.0 99.0 94.5 97.5 97.0 
aAmount of phenobarbital in solution$ mg/1000 ml in 
Gastric Fluid as recorded on the strip-chart readout. 
I 
TJ;;st 6 
I 
I 
98.5 
I 
S9.0 
I 
1@0.0 
I 
100.0 
, I . 
110.5 
I 
Mean + S.D. 
95.3 + 2.4 
95.8·+ 2.5 
96.3 + 2.7 
96.7 + 2.7 
96.9 + 2.8 
S
1
imulated 
I 
1. 
I 
I 
A 
co 
,. 
... 
JOO.O 
"'0 90.0 
,_ 
~ 
ri: 
80.0 
f.~--,o 
~ ... ~ 
c~ 
~ ~-70.0 
:::S(!) 
0 
(f)~- ..en 0 
CD QV. . 
. ....,. 
.. S,g 
=-~ ~.§-50.0 
..0 (/) 
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:E .5 40.0 
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49 
o~~~-r-+~~~~~r-+-T-+-~~-r-+-+-4 
0 D oo ro ~ ~ oo ro ~ oo 
Minutes 
F'igure 5. Mean Dissolution Profile Curve for Product :S. 
.. 
TABLE !X 
Dissolution Data for Product C 
--
Dissolution Phenobarbital in Solution, mg/1000 mla 
Sampling 
Time~ min Test 1 Test 2 Test 3 Test 4 Test 5 !Test 6 Mean + S.D. 
5 25.5 33.0 30.0 21.. 5 21.0 28.0 26.5 + 4.8 
10 53.5 58.0 54.5 65.0 58.5 58.0 57.9 + 4.0 
15 70.0 74.5 65.0 74.5 71.0 72.5 71.3 + 3.6 
20 . 78.5 . 83.0 73.0 79.0 76.5 80.5 78.4 + 3.4 
25 85.0 90.0 . 79.5 82.0 77.0 85.5 83.2 + 4.7 
30 ·89.0 93.0 84.0 85.0 79.0. 88.5 86.4 + 4.8 
35 91.0 94.5 86.5 87.5 84.5 90.0 89.0 + 3.6 
40 93.0 96.0 88.0 89.5 89.0 92.0 91.3 + 3.0 
45 94.5 96.5 89.0 91.5 92.0 93.5 92.8 + 2.6 
50 95.0 96.5 90.0 93.0 94.0 94.0 93.8 + 2.2 
55 96.0 97.0 90.5/ 94.0 95.5 95.0 94.7 + 2~3 
i 
60 96.5 97.0 91.0 95.0 96.5 96.0 95.3 + 2.2 
65 97.0 97.0 92.0· 97.0 97.5 96.0 96.1 + 2.1 
c.n 
9 
--I 
L--- ,_. ... ... ~~-:--" 
., .·,: ." ~.. r 
·-
;;,•~. 
0
, ~.;>~,.,.-.t·:~.,;.t.;":..~~~~~,.;~;:-:rj'~;~~l·~·~.i:£ •. "!-.'• ...... ~~"f:'""~'~-v"·•>•;o" ''""..,._.,"~•' ~·-ooU'•~~- Oh- '•--· 
Dissolution 
Sampling 
Time, min . 
70 
75 
80 
85 
90 
Test 1 
97.0 
97.5 
98.0 
98.0 
98.0 
TABLE IX 
(continued) 
Phenobarbital in Solution, mg/1000 
Test 2 . Test .3 Test 4 Test 5 
97.0 92.5 99.0 98.0 
97.0 93.0 100.0 98.5 
97.0 93.5 101.0 98.5 
97.5 94.5 101.5 99.0 
97.5 95.0 102~0 99.0 
aAmount of phenobarbital in solution~ mg/1000 ml 
Fluid as recorded on the strip-chart readout. 
I' ll_-'---L-'-'------------" 
mla\ 
·I 
']'est 6 
I 
Mean + S.D. 
96.0 96.6 + 2.3 
96.5 97.1 + 2.4 
97.0 97.5 + 2.5 
97.0 
198.0 
I 
97.9+ 2.3 
. 98.3 + 2. 3 
in Simulated Gastric 
. I 
I 
c.n 
..... 
·~ ·.~ ~· -~-:_~ •.• ...;.~ ·:. ... ~ ~- ~ ..... ';~;.,:.:.;·.· ·:."',;,~ ... -~ ... ~t~ •• -» ..... "t.~~ll5bf-1
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Figure 6. Mean Dissolution Profile Curve for Product C. 
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'"l 
:< ~ 
·.·~~ 
~1 
. fl 
~· )' 
.r •. 
' i 
···. i 
?i 
I 
~ 
Dissolution 
Sampling 
Time, min Test 1 
5 0 
10 0 
15 0.5 
20 3.0 
25 7.0 
30 . 13.5 
35 22.0 
40 ·29.0 
45 34.5 
50 39.0 
55 43.5 
60 47.5 
65 52,. 5 
'TABLE X· 
Dissolution Data for Product D. 
1 . 
. Phenobarbital in S.olution, mg/1000 ml;\ · 
Test 2 Test 3 Test 4 Test 5 i 'rest 6 
1, . 
0 0 0 0 0 
0 0· 0 0 0 
2.0 2.0 0 0 2.5 
5.5 5.0 1.5 2.0 6.5 
13.5 12.0 5.0 4.5 13.0 
22 .. 0 23.0 9.0 8.0 20.5 
30.0 32.5. 13.0 12.5 28.0 
36.5 40.0 16.0 17.0 36.5 
42.0 46.0 18.5 21.5 42.0 
46.0 51.0 21.5 24.0 47.0 
49.0 55.0 25.5 26.5 '51. 5 
; 
156.0 52.0 59.5! 29.5 . 28.5 
55.0 62.5 31.5 30.5 1159.5 
Mean + S.D. 
0 
0 
1.2 + 1.1 
3.9 + 2.0 
9.2 + 4.1 
16.0 + 6.7 
23.0 + 8.7 
-
29.2 + 10.5 
34.1 + 11.6 
38.1 + 12.5 
41.8 + 12.8 
45.5 + 13.4 
48.6 + 14.1 
c.n 
w 
j I . -
... .•' . &,. .. ~· .,..-. ,, _.,~ , .. ,_,.j, • ~·- -· . ' "' •" .. ""* , ·~ ·r ·~,.,··· • .L • ' - ·~ '" .. '· , '' ~ . .., ,_. ~---~,.. .-. ~ 
· •. :, .··;.t ..._ .r .... ~-- ..... ':: 
0
s-- ~ •"'"'~"::l"TI&C"'~i"'-'!'t.~;( "."'" .................. ,.,.»,...~""'"'~h~"';\~r .. ,-r .. .;. "'~,.. • ~"'""'"""'·~-~ '"'-$"'--;:"~vff;.."';~~=~¥ ~~:.~lk'.t:.:~~~;(~~~·:.:.r.~\~~.~"'-,:,,~~-'!!:"~~-~;;.;'-~ ,_..,~ .. ~:! 
&& - ' -· .. -------~--_.,. __ _.c.\' ~ - ~- -
IJ."'ABLE X 
(continued) 
I 
Dissolution Phenobarbital in Solutiori, mg/1000 mla I 
Sampling 
'Test 4 I Test 6 Time, min Test 1 Test 2 Test 3 Test 5 Mean + S.D . 
70 55.5 57.0 66.0 ...,.d. f'l .j) ~. v 32.0 62.5 51.2 + 14.6 
75 58.0 59.5 68.5 36.0 34.0 66.0 53.7 + 15.0 
80 61.0 62.5 71.0 37.5 36.5 68.0 56.1 + 15.2 
85 63.5 64.0 73.0 39.0 38.5 70.0 58.0 + 15.3 
90 65.5 66.0 75.0 41.0 40.5 72.0 60 .. 1 + 15.2 
a Amount of phenobarbital in solution, mg/1000 mL iJl Simulated 
Gastric Fluid as recorded on the strip-chart readout. 
c.n 
~ 
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l''igure 7. Hean Dissolution Profile Curve for Product D. 
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Dissolution 
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TABLE XI 
Dissolution Data for Product E 
1. 
Phenobarbital in Solut~on, mg/1000 ~la[ 
Test l Test 2 Test 3 Test 4 Test 5 
i 
'Test 6 
I 
Mean +.S.D. 
0 0 0 0 0 0 0 
20.0 9.5 7~0 ·s.o 4.5 15.0 9.8 + 6.5 
39.0 24.0 20.0 10.0 16.0 27.0 22.7 + 10.0 
49.5 35.5 32.0 20.0 25.5 I ,40, 5 33.8 + 10.6 
58.5 46.5 43.0 29.5 36.5 I 44.3 + 10.4 151.5 
63.5 51.5 48.5 37.0 44.5 
.159. 5 50.8 + 9 .. 7 
·69.0 59.o· 55.0 46.0 54.0 68.0 58.5 + 8.8 
I 
. 72. 0 ~ 67.0 59.5 53.0 62.0 '73 5 
I • 
64.5 + 7.8 
74.0 71.0 65.0 57.0 67.0 ''18. 0 68.7 + 7.4 
I . -
75.5 75.0 ·. 67.5 62~5 71.5 81.5 72.3 + 6.7 
. I. -
77.0 77.5 71.5 1 67.5 75.0 84.0 . 75.4 + 5.6 
I -
78.5 80.0 75.0 I 71.0 78 .. 0 86.0 78.1 + 5.0 
I 
-
I 
I 
/ ~:... •f-o..c,"' ..... ;, : ,:"'~·~ -..4 -':, ·~~ 0 ...... · .. ·(~.: ... _ ...... _ ;: .• ··.w -~~~-:·:,: .. 'h"'' ,;.'f~ ....... ~. ,~. ":':'":-........... ··-~~"-·,~~<,o:~: 
CJl 
m 
' 
I 
. I 
TABLE XI 
· (continued) 
Dissolution Phenobarbital in Solution, mg/1000 mla\ 
Sampling I 
m• . .~.~me, m~n Test l Test 2 Test 3 Test 4 Tes~ 5 '['est 6 Mean + S.D. 
65 79.5 81.0 78.0 73.5 80.0 
70 80.0 82.5 81.0 75.5 81.0 
75 82.0 84.0 83.5 77.5 83.0 
80 ·82. 0 84.5 84.5 78.0 83.5 
85 82.5 85.0 86.0 79.5 84.0 
90 83.5 86.5 87.0 81.0 85.0 
aAmount of phenobarbital in solution, mg/1000 ml 
· Gastric Fluid as recorded on the strip-chart readout. 
j_ 
87.5 79.9 + 
89.0 81.5 + 
90.0 83.3 + 
90.5 83.8 + 
91.0 84 0 7 +. 
92.0 85.8 + 
in !simulated 
I 
~ ~· . . ... ,, z~. ·i·~ ~ · ·- ;~f~: · ·: ~··:'i'~-•- ~~-.~,_,~, _,...;;. .,. -~"- -~·"""'-~- ·:~:o ·~·-~.:" ·~·_.:(:. ;~~~.;·•':: ~~-~ "'"' ~::~-....... ---· .-. 
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Figure 8. Mean Dissolution Profile Curve for Product E. 
' t·'' 
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r; 
Dissolution 
Sampling 
m· . 11.me, m1.n · Test·· 1 
5 3.5 
10 28.0 
15 50.0 
20 63.5 
25 79.0 
30 86.5 
35 92.0 
40 95.0 
45 98.5 
50 100.0 
55 102.0 
60 103.0 
65 103 •. 5 
TABLE XII 
Dissolution Data for Product F 
. 1. 
Phenobarbital in Solutions. mg/1000 mla- I 
TJ~st 6 Test 2 Test 3 Test 4 Test 5 
I o 6.5 3 .. 5 1.0 3.0 
29.5 21.5 16.5 21.0 ~~2. 5 
I 
51.0 41.0 33.5 36.0 j~2. 0 
51.0 45.0 47.5 50.0 ... 
1
7. o 
78.0 64.5 59.0 64.0 . 716.5 
86.0 72.5 70.0 76.5 81:4. 5 
90.0 77.5 78.5 82.5 819.5 
92.0 86.0 I 81.5 82.5 9i2. 5. 
94.0 84.0 . 86.5 90.0 . 9i5. 5 
95.5 87.5 89.0 91.5 917.0 
96.5 89.0 . ! 91.5 93.0 918.5 
I 
97.0 90.0 93.0 95.0 919.5 
97.0 92.0 95.5 96.0 10,0.0 
Mean + S.D. 
2.9 + 2.3 
23.2 + 4.8 
42.3 + 7.1 
52.3 + 6.8 
70.2 + 8.7 
79.3 + 7 .. 3 
85.0 + 6.3 
88.3 + 5.7 
91.4 + 5.6 
93.4 + 4.9 
95.1 + 4.8 
96.3 +· 4.6 
97.3 +· 4.0 
c.n 
<D 
/· ... ;~ 
·Dissolution 
Sampling 
Time~ min 
70 
75 
80 
85 
90. 
TABL~ XII 
( c·ontinued) 
Phenobarbital in Solution, mg/1000 mla 
Test 1 . Test 2 Test 3 Test 4 Test 5 
103.5 97.5 93.5 96.5 96.5 
103.5 97.5 94.0 97.5 97.0 
103.-5· 98.0 95.0 98~5 97.5 
103.5 98.0 95.5 99.0 98.0 
103.5 98.0 96.0 99.5 . 98 0 0 
aA~ount of phenobarbital in solution~ mg/1000 ml in 
Gastric Fluid as recorded on the strip-chart readout. 
Te~~t 6 Mean + S.D . 
I 98.0 + 3.5 10e.s 
1011~. 5 98.3 + 3.3 
lOjl. 0 98.9 + 3.0 
. I 
10l.5 99.3 + 2.8 
I 
101.5 99.4 + 2.7 
I 
'I 
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Figure 9. Mean Dissolution Profile Curve for Product F. 
TABLE XIII 
Dissolution Data for Product G 
Dissolution Phenobarbital in Solution, mg/100 m1a 
Sampling 
Te!st 6 '"". . Test 1 Test 2 Test 3· Test 4 Test 5 Mean + S.D. .~..·lme , mln· ·' . 
I . 
'i 
5 0 3.0 0.5 0 0 ';). 5 ,1;.., 0 1.0 + 1.4 
10 16.0 26.5 18.0 11.0 16.0 
I 
l!~. 0 17·. 8 + 5.1 
15 33.0 43.5 36.5 23.0 30.0 3'~ 5 ~~ G 33.1 + 6.8 
20 47.5 55.0 48.0 33. o. 40.0 4:3 0 5 
. I 
44:.5 + 7. 6 
25 57.5 64.0 56.5 42.0 49.5 5'•) 0 41 • 53.6 + 7.6 
30 65.5 64.0 63.0 50.0 56.5 5~~. 0 59.7·+ 5.8 
I -
35 71.0 75.0 70.0 56.0 62.5 6~L5 
I 
66.3 + 6.9 
. 70.6 + 6.5 40 75.0 79.0 73.5 61.0 68.0 67.0 
78.0 82.5 77.0 65.0 I 45 72.0 71.0 74.3 + 6.2 
I 
. -
50 80.5 84.5 .. . 80.0 69~0 75.0 74.0 
I 
77.2 + 5.6 
55 83.0 86.5. 82.5 ., 72.0 78.0 71~0 79.8 + 5.2 
60 84.5 88.0 84.5 I 76.0 81.0 7~.5 82.3 + 4.3 
65 86.5 89.0 86.5 77.5 83.0 I 82 .. 0 
I 
84.1 + 4.'1 
i . 
I 
I . 
m 
tlj 
-~ 
-~ ~.;· .. ·~ .. ~_,. .. ~- -" ~~- ..,.; • .:;:r~ ._ ~~~ .. :.-~"-"'•-·- ·-,;;'.<jli'_. ~-~- •ll"'-""'·-"-·""'! .. 
Dissolution · 
Sampling 
Time. min Test 1 
70 8'7 .5 
75 88.0 
80 . 88.5 
85 89.0 
90 89.5 
TABLE XIII 
{continued) 
. Phenoharbi tal in Solution, mg/1000 mli. 
Test 2 Test 3 Test 4 Test 5 ~est 6 
90.0 87.5 79.0 85.0 83.5 
90.5 89.0 81.5 86.5 85.5 
91.0 90.0 83.0 88.0 86.5 
.91. 5 90.0 84.0 88.5 87.5 
91.5 91 .. 0 85.0 90.0 188.0 
Mean + S.D. 
85.4 + 3.9 
86.8 + 3.2 
87.8 + 2.8 
88.4 + 2.6· 
89.2 + 2.4 
aAmount of phenobarbital in solution, mgflOOO ml in !Simulated 
Gastric Fluid .as recorded on the strip-chart readout. 
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Figure 10. Mean Dissolution Profile Curve for PrtiduGt G. 
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TABLE XIV 
Summary of Physical Property Data for the 1 ~rocfucts 
· Mean Tablet Mean Tablet /Disintegration Mean Dissolution 
Product Weight, mg Hardness, kp Time, min Rate? TeO%' minq 
A. 178.5 3.5 11.43 I 25.0 
B 300.4 3.5 1.47 14.5 
c 349.1 10.3 1.03 10.5 
D 176.2 4~9 4.05 . I 88.5 
E 206.2 4.1 3.68 36.0 
F 180.3 6.9 11.93 21.0 
G 228.9 9.1 0.73 I 30.0 
"Mean Dissolution Rate,· Tso% in )nin .• represents the val[ue as extra-
polated from the Dissolution Profil~s Curves and is the time i 1n minutes re-
quired for 60% of the labeled amount of Phenobarbital in the t:ablets to 
dissolve. I 
I Q') 
Q') 
TABLE XV 
Standard Curve Data for EMIT Phenobarbital As::;;;ay 
. I 
Serum b.A - 6.A0 Values at 340 nm Phenobarbital 
Concentration; 
1-!g/ml Trial I. Trial.II Trial III M~an .:_S.D. 
·o.s 0.059 0.057 0'.053 I 0. 0156 2: 0. 0031 
1:.0 0.086 0.083 0.080 0. 0183 + 0 0 0030 
2.0 0.109 0.111 0.108 0.119 :t. 0.0015 
4.0 0.154 0.151 0.151 0.1.52 + 0. 0017 
I -
8.0 0.197 0.194 0.195 0.1:95 + 0.0015 
I 
I 
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Figure 12. Standard Curve for the EMIT Phenobarbital Assay. 
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TABLE XV! 
Serum Phenobarbital Concentration Levels for Prolduct A 
Serum Phenobarbital Concentration, pgfml 
Serum . Group - Sub.j ect 
.Sampling 
Time, h.r A-1 A-2 B-1 B-2 B-3 Mean + S.D. 
0.5 2.10 1.70 4.50 2.00 4.10 2.88 + 1.31 
1.0 2.10 2.25. 4.1'0 2.40 4.00 2.97 + 0.99 
2.0 l. 90 l. 90 4,20 3.05 2.40 2.69 + 0.97 
4.0 1.85 1.70 3.60 2.70 2.55 2.48 .:!:. 0 .. 76 
8.0 1.80 2.00 3.90 3.50 2.95 2.83 + 0.92 
16~0 1. 55 1.20 3.20 3.80 3.30 2.61 + 1.16 
32.0 1. 35 ·1. 50 3.30 2.60 3.20 2.39 + 0.92 
I 
64.0 1.30. 1.20 2.70 2.40 1.80 1. 88 + 0. 66 
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Figure ·13. Mean Serum Concentration-Time Curve for Product! A .. 
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Serum Phenobarbi.tal Concentration,. 1..1 g/m1 
Serum Group - Subject: 
Sampling 
'T' • . • ~lme: .nr A-1 A-2 B-1 B-2 B ':I -~ Mean + S.D. 
0.5 1.00 2.80 0 0.78 2.50. 1.42 + 1.19 
1.0 1.00 3.55 0.50 1.75 2.90 1.94 + 1.28 
2.0 1. 50 3.00 1.50 2.20 3.45 2.33 + 0.88 
4.0 3.20 2.85 2.10 2.10 3.10 2.67 + 0.54 
8.0 2.30 2.45 2.20 2.20· 2.90 2.41 + 0.29 
16.0 2.75 2.45 2.20 l. 75 1.90 2.21 + 0.41 
32.0 1. 65 . 2.50 1. 95 2.00 1.75 1. 99 + o. 37. 
! ·. 
. 64.0 0.90 1.00 1.55 1.55 1.15 1.23 .:t 0.3l 
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Figure 14. Mean Serum Concentration-Time Curve for Product B; "" l:\:1 
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TABLE XVIII 
Serum Phenobarbital Concentration Levels for Prbduct C 
I 
Serum Phenobarbital Concentrs.tion, !l.gjml 
Seru..m · · .·Group - Subject 
·~ 
Sampling 
I Time, hr A-1 A-2 B-1 . B-2 B-3 Mean + S.D. 
0.5 2.90 2.60 1.50 2.25 3.50 I 2.57 + 0.71 
1.0 2.40 2.80 2.65 3.20 4.70 , I 3.15 + 0.91. 
2.0 2.40 2.80 3.90 3.70 5.10 3.58 + 1.05 
4.0 2.00 2.90 4.50 3.20 4.30· 3·. 38 + 1. 03 
8.0 2.20 2.40 3.20 4.00 4.00 3.16 + 0.85 
16.0 2.10 2.60 3.40 3.80 3.80 3.14 + 0.76 
32.0 2.60 2.70 3.55 3.40 2.90 3.03 + 0.42 
64.0 2.10 2.10 3. 1i5 2.65 1.90· 2.38 + 0.51 
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Figure 15. Mean Serum Concentration-Ti~e Curve for Product c. 
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TABLE XIX I 
Serum Phenobarbital Concentration Levels for Profuct D 
Serum Phenobarbital Conc.entrat.ion, 11 gfml 
.Group- Subject 
A"""l A-2 B-1 · B-2 B-3 Mean + S.D. 
1.50 0.80 1.07 2.95 1.30 1.52 + 0.84 
2.70 0.70 2.70 3.75 2.10 2.39 + 1.12 
2.95 2.10 2.90 3 •. 20 4.00 3.03 + 0.68 
1.90 2.20 2.55. . .3 .15 3.60 I 2. 68 + o. 69 
2.65 1.60 3 .. 30 2.75 3.90 2.84 + 0.85 
2.40 1.90 2.70 2.70 3.10 2.56 + 0.44 
2.60 1.85 2.80 ·2.50 2.80 . 2.51 + 0.39 
0.80 2.00 
. I 
2.4q 1.95 2.30 1.89 + 0.64 
·--:.- -~:" c;·;" ·, _, .... ~-~ ·>."-~ ··","S'::··~ -·.:.. , .. :·::· ...... ' .. ·· ·~k .. ·-~· ... l" ... ,. 
~ 
\Jl .· 
-E 
......... 
en 
::l 
... 
4.00 
§ 3.00 
0-----· ltJ . 
tJ I ~~ += e +-c: 
CD 
0 
c: 
0 (.) 2.00 
. tJ 0~0~ 
-g 
...a 
ll... 
0 
..a 
0 
c: Q) 
..c: 
a. 
E 
::J ,_ 
Q) 
en 
~0 
1.00 
I 0-0 I I I I ' I . I I I I I I I I I f ~ I ,:< I JL--f 
6 2 4 6 Sl 16 32 . 64 
Hours 
I 
Figure le. 
Mean Serum Concentration-Time Curve for Product D. 
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TABLE XX 
Serum Phenobarbital Concentration Levels for Product\E 
._1. 
Serum Phenobarbital Con.c.entration ,. J..t gjm,l 
--
Serum 
Sampling 
Time, hr A-1 
Group - Subject 
. I 
A-2 B-1 B-2 B-3 Mea.n + S.D. 
I -
0.5 0.98 
1.0 . 1.15 
2.0 1. 50 
i 
1.49 L.'$5 1.30 1..60 l.r :': 0.23 
2.95 101-5 1.00 .1.30 1.15 + 0.81 
2.1\8 + 0.61 ·. 3.10 2.10 1.80 2.40 
I 
4.0 1.90 3.15 2.45 1.80 3.10 2 .41~ + o. 64 
8.0 1.70 2.85 3.05 3.00 3.10 I 2. 7,r . + o. s9 
16.0 2.30 2.80 3.65 3.80 3.55 
I 
3.22 + 0.64 1-
32.0 1. 80 2.50 2.55 3.50 1.66 2.41 + 0.75 
1-
64.0 1.75 2.10. 2.30 ! 2.15 2.50 2 .ri:> + o. 28 
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Figure 17. 
Mean Serum Concentration-Time Curve for Product E. I 
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TABLE XXI 
Se:t'um Phenobarbital Concentration Levels for Proruct F 
Serum Phenobarbital Concent.ra tion, il g/ml 
Group - Subject 
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Figure 18. Mean Serum Concentration-Time Curve for PropuctiF. 
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TABLE XXII. 
Serum Phenobarbital Concentration Levels for Prc>duct G 
I 
Serum Phenobarhi tal Concentration$. 11 gjml 
Serum Group - Subject 
Sampling 
Time, hr A-1 A-2 B-1 B-2 B-3 Mean + S.D. 
0. 5. 1.80 1.60 1.10 0~89 1.30 1.34 + 0.37 
1.0 2.90 1.95 2.45 2.80 2.10 2.44 + 0~.42 
2.0 3.05 L90 3.35 3.20 3.50 3. 00 +. 0. 64 
4.0 3.05 3.40 3.60 3.40 3.80 3.45 + 0.28 
. -
8.0 2.80 3.00 3.65 3.75 3.60 3.36 + 0.43 
16.0 2. 4!::· 2.80 .3. 80 3.65 3.75 3.29 + 0.62 
' i 
32.0 2.15 3.05 3.10 3.30 3.50 3.02 + 0.52 I 
2.30 
f 64.0 1.70 2.60 2.60 1.95 2.23 + 0.40 ! 
-
t 
I 
r 
~ 
. 
~ 
1 
f 
00 r 1-'. 
t ,. 
, . 
• f 
t 
f 
~ 
t· 
........ _ ....... -···· 
-~ 
en 
::L 
.... 
c 
0 
·-...... 
e 
+-
c 
Q) 
0 
c: 
0 (.) 
0 
.... 
---
..c 
~ 
0 
..c 
0 
s: 
Q) 
..c 
a.. 
E 
;::, 
4~00 
- I 
.· __ · ~· /.~ . 
• 
I -
- . . ... , t•~.Y-<..._ 
.\ 
\ 
~ II , I 
I 0 .. I I . ' I 8 I I I i I I I I I I 1-h?' I . Jf" I 7~ 
- Ia 16 32 64 
Hours I 
Figure 19. Mean Serum Concentration-Time Curve for Product G. ! 
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Figure 20. Composite Mean Serum Concentration-Time Curves. 
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TABLE XXIII 
Summary of the Bioavai1ability Data for the 7 
Mean Peak Serum 
Phenobarbital Time of Mean Peak 
Concentration, Serum Phenobarbital 
11gjml Concentration, hr 
-
2.97 1.0 
2.67 4.0 
3.58 2.0 
3.03 2.0 
3.22 16.0 
3.53 2.0 
3.45 4.0 
-I -
I Products 
l 
J[ean Area Under the 
I Serum Concentration-
' Time Curve, (ilg/m1) 
.\ x hra 
150.88 
122.10 
186.60 
153.38 
160.01 
176.42 
185.16 
• I 
aMean Area Under the Serum Concentration-Time Chrve (llgfml) x hr 
wa.s determined by using the "Trapezoidal Rule" for observations over a 
period of 0 to 64 hr. I 
co 
Cl 
Product 
c 
A 
TABLE XXIV 
Statistical .Analysis of Product A.' BioavaiJ!,ability 
0.5 
2.57 
2.88 
A. Experimental Results 
Serum Sampling Time~ hr 
1.0 2.0 4.0 8.0 16.0 3'12.0 
Mean Serum Phenobarbital Concentration;! ~gjml 
3.15 
2.97 
3.58 
2.69 
3.38 
2.48 
3.16 
2.83 
3.14 
2.61 
C = Reference Product 
3 03 
2 39 
64.0 
2.38 
1.88 
Absorption 
Scorea 
121.95 
103.65 
aThis value for each 
phenobarbital determinations 
. . i product represents the total of the serum 
at all sampling times for ' subjects. 
00 
0') 
TABLE XXIV 
(continued) 
I 
_ _ _ __ -~· -~n-~lysis a~-variance -a~~ ~a:~r~~-An:rsis 
Term 
Between 
C and A 
Between 
.Times 
Between 
Subjects 
Within c· 
Within A 
Residual 
Total 
Degrees of 
Freedom 
1 
7 
4 
39 
39 
67 
79 
Sum of 
Squares 
4.19 
7.00 
29.92 
26.54 
35.01 
24.63 
65.74 
Mean 
Square F p 
4.19 11.32 < o. 01· 
1. 00 2.70 < 0. 05 
7.48 20.22 < 0. 001 
0.68• 
1.32 > 0.10 
0.90 
s 2=0.37 s = 0.61 
00 
-..J 
TABLE XXV. 
Statistical Analysis of Product B · Bioavaiilabil~ity 
A. Experimental Results 
Serum Sampling Time, hr 
0.5 1.0 2.0 4.0 8.0 16.0 32.0 64.0 
I 
Mean Serum Phenobarbital Concentrationl ~gfml 
I Absorption 
Product I Scorea 
. I 
c 2.57 3.15 3.58 3.38 3.16 3.14 a.o3 2.38 . 121.95 
B 1.42 1.94 2.33 2.67 2.41 2.21 JJ .• 99 1.23 80.98 
C = Reference Product 
aThis value for each product represents the 
phenobarbital determinations at a;ll sampling times for 
of the serum 
1 subjects. 
! 
... ,~ ~· .;., ..,;.,.. •,'":;..,(1";::.~ ... :,..-w•" .... -::: -::.,. ......... 
00 
00 
Term 
Between 
Cand B 
Between 
Times 
Between 
Subjects 
Within C 
Within B 
Residual 
Total 
TABLE XXV 
(continued) 
B. Analysis of Variance ·and Factorial 
Degrees of 
Freedom 
l 
7 
4 
39 
39 
61 
79 
.......... _., ~ •• "1-~-· ........ 
Sum of 
Squares 
20.98 
13.26 
9.46 
26.54 
26.86 
30.68 
74.38 
Mean 
Square 
20.98 
1.89 
2.36 
0.68 
0.69 
s 2=0.46 
I 
I . 
Analysis 
I . 
F p 
45.61 < 0. 001 
4 .11' < 0. 001 
5.13 < 0. 001 
1. 01 > 0. 50 
s = 0.68 
co 
<0 
TABLE XXVI 
Statistical Analysis of Product D Bioa~~il~bility 
A.· Experimental Results 
Serum Sampling Time, hr 
I 
0.5 1.0 2.0 4.0 8. 0 16.0 321.0 64.0 
Mean Serum Phenobarbital Concentration, ~gjml Absorption 
Product 
I 
Scorea 
- . I 
3.S8 3.16 3.14 3.f3 2.38 c 2.57 3.15 3.58 
D 1.52 2.39 3.03 2.68 2.84 2.56 2.f>l 1.89 
I 
C = Reference Product 
I 
aThis value for each product represents the to tali. of the serum 
phenobarbital determinations at al+ sampling times for a]l subjects. 
i 
••,.. '""' ~:~-· ~ ::>:?.._;.',T.>-.:;.r~;~~·~:-.~·C- - ...... "-~" 
121.95 
97.12 
CD 
0 
Term 
Between 
C and D 
Between 
Times 
Between 
Subjects 
Within C 
Within D~ 
Residual 
Total 
TABLE XXVI 
(continued) 
B. Analysis of Variance and Factorial Anal~sis 
Degrees of 
Freedom 
1 
7 
4 
39 
39 
67 
79 
,. ~·. · ...... ~" ' . 
Sum of 
Squares 
~ 7. 71 
13.31 
17.39 
26.54 
26.17 
' f 
22.:01 
60.42 
Mean 
Square 
7.71 
l. 90 
4.35 
0.68 
0 .~67 
2 
s =0.33 
I 
' 
F 
l3.36 
I 
5.76 
]3.18 
II 
.01 
I ~ 
I 
p 
< 0. 001 
< o. 0'01 
< 0. 001 
> 0. 50 
s = 0.57 
<.0 
~ 1-' 
.--'~' .. .. -- -~ 
Product 
c 
.E 
TABLE XXVII 
Statistical Analysis of Product E Bioavailability 
0.5 
2.57 
1.35 
. A. Experimental Results 
Serum Sampling Time, hr 
1.0 2.0 4.0 8.0 16.0 32.0 64.0. 
Mean Serum Phenobarbital Concentration, ~gjml 
3.15 
1.51 
3.58 
2.18 
3.38 
2.45 
3.16 
2. 74 
3.14 
3.22 
C = Reference Product 
3.03 2.38 
2.41. 2.16 
Absorption 
Scorea 
121.95 
90.23 
aThis value for each product represents the total of the serum 
"phenobarbital determinations at alrl sampling times for all. subjects. 
~ .... ~.~ 
. ~-'~ --------~-......:.;.~~~~~-. _ _-··c;_e:::··' ,._, ;c~· ..... ~;···;:· . ~- ~....... . ;~--~ -~-:~·;. !_0::: . ~·~-:.: .. ~:;;_~~~~- • ::.·-.:_ •. _:_~-
c.o 
~ 
I 
I I . 
TABLE XXVII 
(continued) 
B. Analysis of Variance and Factorial Analysis 
Degrees of Sum of He an 
Term Freedom Squares Square F 
Between 
C and E 1 12.59 12.59 29.98 
Between 
Times 7 12.33 1.76 4.19 
Between / 
Subjects 4 10.70 2.67 6.36 
Within c 39 26.54 0.68 
1.06 
Within E 39 24.79 0.64 
Residual 67 28.30 s 2=0.42 
Total 79 63.92 
·.:;~~.-::····· - ;".::·;:.... 
.......... ----------------~~~~ 
. :.~ .. ' ·~·'.· ... 
., ·- ·-
p 
< 0.001 
< 0.001 
< 0.001· 
> 0.50 
s = 0.65 
to 
w 
I ·~ 
,,,, ,,,,,,,,,, "'''' c' ~ 
TABLE.XXVIII 
·< 
Statistical Analysis of Product i:.Bioav~ilability 
A. Experimental /Results 
·serum Sampling Time~ hr 
0.5 1.0 2.0 4.0 8,0 16.0 32.0 64.0 
Mean Serum Phenobarbital Concentration,. ].Jlgjml Absorption 
Product 
("' 2.57 3.15 3.58 3.38 3.16 3.14 3.02 2.38 ....... 
F 2.27 2.85 3.53 3.09 3.19 2.92 2.81 2.31 
C = Reference. Product 
aThis value for each product represents the total of the serum 
phenobarbital determinations at all sampling times for all subjects. 
Scorea 
121.95 
114.85 
c.o . 
~ i 
i 
I 
-<:~;:f'"tc?~"'"''~:'c" ~ ·'.r ::_ · ::- -- · ~ ;- :;,,-- :;;;~:.:- ~~~:-----~o:=- .;: "_:""- ~ - --"' ' -- J 
Term 
Between 
C and F 
Between 
Times 
Between 
Subjects 
WithinC 
Within F. 
Residual 
Total 
.... 
.... ·' 
B. 
TABLE XXVIII 
(continued) 
Analysis of Variance and F~ctoria1 Analysis 
Degrees of Sum of Mean 
Freedom ·Squares Square F p 
1 0.63 0.63 1.80 > 0.10 
.7 11.54 1.65 4. 71' < 0. 001 
4 7.92 ·1.98 5.66 < 0. 001 
39 26.54 0.68 
l. 58 > o. 05 
39 16.68 0.43 
i 
'67 23.76 s 2=0.35 s·=·0.59 
79 43.85 
···~":· .... · 
-!··:. ·~· . .;;.. .. ·"<· 
.,,_ .- - ·-~·· 
(.0 
CJ1 
I, 
!1 . 
-·--· --~--=~·------ ----~·=----~. ·--------·-~:)d~':'\:JI.J,J,.,....,.·; ~ 
Product 
c 
G 
TABLE XXIX 
Statistical Analysis. of Product u·.Bioa~ail~bility 
I Oo 5 
2.57 
1.39 
A. Experimental Results 
Serum Sampling Time, hr 
1.0 2.0 4.0 8.0 16.0 32.0 
Mean Serum Phenobarbital Concentration, ug/ml 
3.15 
2.44 
3.58 
3.00 
3.38 3.16 3.14 
3.45 3.36 3.29 
C = Refe~ence Product 
3.03 
3.02 
64.0 
2.38 
2.23 
AbsorPtion 
Sc~rea 
121.95 
110.64 
aThis value for each product represents the total of the serum 
phenobarbital determinations at atl sampling times for all subjects. 
; 
_ .. - ,-:, ·:;....--. .-,.-,.,;~ . . ::"" ~->·-· :,. .;, "'-.:.: 
. . ·.::~?:;:~. ;: .. _ ._-;..~. . . .J-' 
..... ~. ,,. ,,._. ..•. ,..__,_._ .·,;::::-- - - -·- --
_____ .,_ :~·:.:·:·:.~-:-·;;< -- .:- .=- '"'- -~::::.. :.-::=::- . ._ -·· -~ ·-·· ....:._ . __ -,. 
c.o 
G) 
Term 
Between 
C and G 
Between 
Times 
Between 
Subjects 
Within C 
Within·n 
Residual 
Total· 
<: 
~--------~--------===-·==-==--------------------,-¥~ 
TABLE XXIX 
(continued) 
B • .Analysis of Variance. and Factorial Analysis 
Degrees of Sum of Mean 
Freedom Squares Square F 
1 1.60 1.60 4.71 
7 19.21 2.74 8.06 
4 10.06 2.51 7.38 
39 26.54 0.68 
1. 05 
39 25.40 0.65 
67 22.67 s 2=0.34 
79 53.54 
.......... 
"~; ..... ;· :. :<-~ 
·-· ··., •'. 
. ~ ': .:· 
p 
<o.o5 
<o. oo1 
<0.001 
>0.50 
s = 0.58 
<.0 
..:) 
DISCUSSIONS AND CONCLUSIONS 
For products to meet the compendia! requirements 
of the Weight Variation test as stated in the USP XIX for 
uncoated tablets, the tablets must conform to. certain 
weight variation tolerances which are expressed. in terms 
of the percentage difference from the mean weight of a 
sample of 20 individually weighed whole tablets. 
Uncoated tablets that exhibit a mean weight in the 
.range of 130 mg through and including 324 mg are allowed 
a 7.5% variation, wherBas uncoated tablets with a mean weight 
of more than 324 mg are allowed a 5.0% variation. In ad-
dj_tion, the weights o:f not more than. 2 of the tablets from 
the sample may differ from the mean weight by more than the 
indicated percentage and also no tablet may differ by more 
than double the indicated percentage (56). 
Products A, B, C) D, E, F, and G exhibited a mean 
.. 
weight of 178.5, 300.4, 349.1, 176.2, 206.2, 180.3, and 
228~9 mg, respectively. All of these products met the com-
pendial requirements for the Weight Variation test for un-
coated tablets as stated in the USP XIX (Table III, p. 35). 
Content uniformity was therefore also demonstrated through 
the Weight Variation test for all of the phenobarbital.pro-
ducts employed in this study. 
The USP XIX defines complete disintegration as that 
98 
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.. 
state in which any residue of the tablet, except fragments 
of insoluble coating, remaining on the .screen of the test ap-
paratus · is a soft mass having no palpably firm core. To 
meet the compendial requirement as stated in the USP XIX 
Phenobarbital Monograph, phenobarbital tabl~ts mtist com-
pletely disintegrate in 30 min {57). 
· Products A, B, C, D, Ei F, and G exhib~ted dis-
integration times of 11.43, 1.47, 1 .. 03, 4~05, 3.68; 11.93, 
and 0.73 min, respectively, with all of the products meeting 
the compendial requirement (Table V, p. 39). 
For a solid dosage form, suitable dissolution charac~ 
t;eristics are an important property, since the bioavail-
ability of a drug is dependent upon having that drug .in the 
dissolved state. 
The mean dissolution profiles for all the products. 
tested resulted in smooth uniform curves {Figs.. 4-10, pp. 46, 
49, 52, 55, 58, 61, 64). Although the data points at the 5~ 
10, 15, and 20 min intervals do not fall on the line for 
Product F, the curve is the line representing the best fit 
since these data points fall within the standard deviation 
observed·(Table XII, p. 59, Fig. 9, p. 61). 
Dissolution rates are the times taken to release a 
certain amount of the labeled drug in a solid dosage form. 
The time in minutes required for 60% of the labe~ed amount 
of phenobarbital in the tablets t6 dissolve as extrapolated 
from the mean. dissolution profile curves was used as the 
'B..ii2£&JUiEM LUbE &&& M«<i.&&iM4i&MZW . AWl £LEX ZA 
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criteria to establish the mean dissolution rate (T60%) of 
each product. These values were then used to compare the 
mean dissolution rates for the products tested. On this 
basis, Product C exhibited the fastest mean TGO%' followed 
by Products B, F, A, G, E, and D. On comparison of all 
the phenobarbital products tested, Product D exhibited the 
slowest mean T60~ (Fig. 11, p. 65, Table XIV, p. 66). This· . /0 
~lower rate of dissolution may be due to pharmaceutical 
formulation factors. 
Even though variations in tablet hardness and in 
dissolution were observed for all the phenobarbital tablets 
tested, no comparisons can be made because there are no com--
pendial standards at present for these physical properties. 
The extent and rate of bioavailability can be charac-
terized by three parameters: 1) peak serum.concentration~ 
2) time· of peak serum concentration, and 3) the area under 
the serum concentration-time curve (AUC). The magnitude of 
the peak serum level is a function of the rate and extent of 
drug absorption, whereas the tim~ of peak serum concentration 
is a function of the rate of drug absorption .into the physi-
ological system. The AUC indicates the relative amount of a 
drug absorbed from a dosage form into the physiological system. 
Product C attained the highest· mean peak serum con-
centration level of all the phenobarbital products tested 
and was followed by Products F, G, E, D, A, and B (Table 
XX I I I , p . 8 5 ) . 
--------------·-------------·- . 
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The most rapid mean peak serum concentration, 1 hr. 
was achieved by Product A {'rable XXIII, p. 85)~ Products 
C, D, and F attained their mean peak serum concentrations 
in 2 hr (Table XXIII, p. 85). The time of mean peak serum 
concentration for Products B and G was 4 hr, while for 
Product E it was 16 hr (Table XXIII, p. 85). ·\ 
Bioavaila1JiJ.lty . is estimated best by the AUC. . Product 
C exhibited the greatest mean AUC and was followed by Pro-
ducts G, F, E, D, A, and B (Fig. 21, p. 84, Table XXIII, 
p. 85). Therefore, Product C was selected as the refere~ce 
product for the statistical analysis by "Analysis of Variance. 11 
These analyses of product bioavailability (Tables 
XXIV-XXIX, pp. 86-97) demonstrated that there was a sig-
nificant difference among Products C and A (p < 0. 01), Pro-
ducts C and B {p < 0.001) 3 Products C and D (p < 0.001), 
Products C and E (p < 0.001), and Products C and G (p < 0.05). 
However, no significant difference was demonstrated between 
Products C and F (p > 0.10). 
For dissolution data to be useful in the prediction 
of product bioavailability, a correlation between dissolution 
rate and the area under the serum concentration-time curve 
should exist. In order to demonstrate this correlation among 
the p'roducts tested: 1) the mean T60% was established (see 
Table XIV, p. 66) and ranked on a numerical scale from 1 to 
7, where 1 indicates the fastest mean T60% and 2) the mean 
AUC was established (see Table XXIII, p. 85) and ranked 
:q 
•' 
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on a numerical scale from 1 to 7~ where 1 indicates the 
greatest mean AUC. The results of these comparisons are 
presented in 'J.'able XXX (p. 103 ) .• 
Products A, B, D, E, and G demonstrated no correla-
tion between the mean •r60% and the mean AUC (Table XXX, p. 
103). Products C and F demonstrated a definite correlation 
between the mean T60% and the mean AUC 0Table XXX, p. 103). 
In addition, Products C and F demohstrated very similar mean 
peak serum concer\trat ion levels, as well as exhibiting 
identical times to achieve their mean peak serum concentra-
tions (Table XXIII, p. 85). Furthermore, the statistical 
analysis demonstrated that theie was no significant difference 
(p > 0.10) between these phenobarbital products (Table XXVIII, 
p. 94). In conclusion, Products C and F can be designated 
as pharmaceutically equivalent products that-.are also bio-
equi valent. · 
LJL lll!RU1l 
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TABLE XXX 
Correlation Data Profiles for the 7 Products 
Dissolution Data Bioavailability Data 
Mean Area Under the 
Product 
Mean Dissolution Rate 
TSO%' min Rank a 
Serum Concentration-Time Curve 
AUC, (~gjml) x hr Rank b. 
A 
B 
cc 
D 
E 
Fe 
G 
25.0 
14.5 
10.5 
88 .. 5 
' 
36.0 
21.0 
30.0 
4 150.88 
2 1:22.10 
1 186.60 
7 153.38 
6 1E30. 01 
3 176.42 
s· 185.16 
aNumerical rank assigned to the mean T60% from 1 to 7, where 1 indicates the fastest mean T60%. 
0 
bNumerical rank assigned to the mean AUC from l.to 7, where 1 indicates the 
greatest mean AUC. 
6 
7 
1 
5 
4 
3 
2 
0 Indicates Products that are pharmaceutically equivalent and also b.ioequivalent. 1-' 0 
w 
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I 
SUMMARY 
.The physical properties of Phetiobarbital Tablets; 
USP, 100 mg, from 7 manufacturers were characterized by 
determining tablet weight, weight variation, hardness, 
disintegration time, and dissolution rate. 
The dissolution profiles for these products were 
characterized by using the Beckman Spectrophotometric System, 
an analytical instrument specifically designed for tablet dis-
solution studies. 
'l'he bioequivalency among these products were also de-
termined by conducting bioavailabi1ity studies employing 5 
normal, healthy human adult male subjects. 
All the products tested conformed to the USP XIX 
Weight Variation and Disintegration tests. The physical 
property data showed variations in tablet hardness and in 
dissolution among the 7 products. 
The bioavailability data of these products exhibited 
variances in mean·peak serum concentration levels, time of 
mean·peak serum concentration levels, and the mean area under 
the serum concentration-time curves. 
Statistical analyses of the bioavailability data demon-
strated significant differences among 5 of the products, while 
1 of the products showed no significant difference in regards 
to the assigned reference product. 
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A correlation between the mean dissolution rate and 
the mean area under the ~erum concentration~time curve was 
observed between 2 of the products tested. 
i 
j ! 
' •{ 
., '.; 
_. ,.;·;. 
. ~~ : 
BIBLIOGRAPHY 
1. Wagner, John G., J. Pharm. Sci.,_50:359-387 (1961)." 
2. Garrett, Edward R., Acta. Pharmacal. Toxicol., 
29:1-29 (1971). 
3. National Research Council, Division of Medical Sciences, 
Drug EfficacY, Stud~: Final Report to _:the Commissioner 
of Food and Drugs, Food and Drug Administrat-ion, 
National-Academy of Sciences, Washington, D. C., 
1969' pp'. 1-2. 
4. Ibid., pp. 1, 39. 
5. Ibid. , pp. 4~-5. 
6. Anon., FDA: J3ep_o~! on Enforcement and Compliance~ 1964, 
pp. 3-4. 
7. op. cit.,(:~) p. 57. 
8. Ibid., (3), pp. 61, 63.1> 79, 80, 86, 87., __ 88. 
9. Anon., Med. )Vo!:.!E. News, 15:71-88 (1974). 
10. Barr, William H., Drug _Inf. Bull., .9.:27-4~ (1969). 
11. Brice, George W. and Henry F. Hammer, JAMA, 208:1189-1190 
(1969). 
12. Blair, Donald C., Roger W. Barnes, E. Lincoln Wildner, 
and William J. Mur:ray, JAMA, 215:251-,254 (1971). 
13 .. ;. Lindenbaum, John,. Mark H. Mellow; Michael 0 .. Blackstone, 
and Vincent P. Butler, N. _;Engl.!!_. Med., 285:1344-
1347 ( 19'71). 
14. Varley, Alan B., JAMA, 206:1745-1748 (1968). 
15. · Meyer, M. C., G. W. A. Slywka, R. E. Dann, and P. L. 
Whyatt, J. _!?h_arm. Sci., 63:1693-1698 ( 1974). 
106 
-... 
. ~­
.' 
.<'; 
,l' 
107 
16. Poole, John W., Se~in. Drug Trea:!:_., 1:148-176 (1971). 
17. Koch-Weser, Jan, N. Eng. J. Med., 291:233-237 (1974). 
18. Nikore, H. L.~ Indian J. Hosp. Pharm., 4:181-192 (1967). 
19. Speiser, P., Pharma Int., 3/71:5-.16 (1971). 
20. IJevy, Gerhard and Eino Nelson, JAMA, 177:689-691 (1961). 
21. Davis, S. S., Br. Med. J., !:102-106 (1972). 
22~ Noyes, Arthur A. and Willis R. Whitney, J. Am. Chern. 
Soc., _19: 930-934 ( 1897). - -
23. Rosenstein, Sol ana .t-Je'ter P. Lamy, Am. J. Hosp. Pharm., 
. 26: 598-601 ( 1969) . 
24. Sokoloski, Theodore, D.,~· Phar~., 3:15-18 (1968). 
25. Blake, Martin I. , J. Am. Ph arm. Assoc. , NS 11: 603-·611 
( 1971). 
26. The United St~te~ Pharmacopeia, Nineteenth Revision. 
Board of Trustees of the United States Pharmacopeia! 
Convention. Inc., Hockville, :MD, 1975, pp. XVI, 705. 
27. Pocock, Stuart. and C. T. Rhodes, Can. J. Pharm. Sci., 
9:61-63 (1974). 
28. ~E· cit. (26) p. 650. 
29. Ibid., (2~), p. 651. 
30. Ibid., (26), pp. 651, 706. 
31. Harris, Lewis E., Drug and Cosmet. Ind., 106:42-43, 
138-139 ( 1970) .-. - -
· 32. Academy of Pharmaceutical Sciences, Guidelines For 
Biopharrnaceutical Studies· In :11-fa·n;- American --
Pharmaceutical -As.socia.tion-,-Washington~ D. C., 
1972, p. 6. 
33. Harris, Lewis E., Drug and Cosmet. _!nd., 107:38-40, 143 
(1970). 
34. Hayes, Thomas A., pyug ~nd Cosmet. Ind., 109:44-47, 
132-138 (1971). 
35. Moss, Jack N. and C. T. Rhodes, Can. J. Pharrn. 
9:30-31 (1974). 
•' . 
; •' 
~: _l, -
~· 1: .~t 
tr, • ·~ • 
~ ~ .) (l 
\ 
. . ~
36. National Prescription Audit: General Information 
--Report., HIS-~America, Ltd.~ Ambler, PA, 19'74, 
pp. 22-25. 
37. 
38. 
Sedam, .Richard L., Alfonso R. Gennaro, and Arthur 
Osol, J. P!_F~£El· Sci., 54:215-218 (1965). 
Leuall"E;n··, E. E.·, J. Am. Pharm. Assoc. Pract.· Ed~ · 
10:722--724 ( 1949 )-. -- ' 
"108 
39. Krause, George M. and John.M. Cross, J. Am. Pharm. 
Assoc. Sci .. Eq., 40:137-139 (1951)-:- --
LJO. Urdang, Arnold and E. Emerson Leua1len, J. Am. Ph~. 
Assoc. Sci. Ed., 45:525-526 (1956). 
---- ---- - - . 
41. Edmonson, 'I'. D.. and J: E. Goy an, J. Ain. Ph arm. Assoc. 
Sci. Ed. , :1'{.; 810-812 ( 1958). - - ----
42. Mesley, R. J., R. L. Clements, B. Flaherty, and K. 
Goodhead, J.. 1-:!_larm. Pharmacol. , 20:329--340 ( 1968) . 
43. Clements, J. A. and D. Stanski 3 Can. J. Pharm. Sc_:!:_. , 
6:9-14 (1971). 
44. Jacob, James ~I'. and Elmer l\L Plein, J. Pharm. Sci. 
_57: 798-801 ( 1968). 
45. Jacob, James '1'. and Elmer M. Plein, J. Pharm. SeL 
57: 802-805 ( 1968) •· 
46. Solvang, Sissel. and Per Finholt, J. Pharm. Sci., 
59:49-52 (1970). 
47. op. cit. (26), pp. 670--671. 
48. Ibid. (~6), p. 650. 
49. Beckman Instr~ments, Inc., Industrial Product Data 
Sheet: Model 25-7 System for Tablet Dissolution 
Testing, Fuilerton. CA, _19?4. 
50. Booker, Harold E. and Barbara A. Darcy,· Clin. Chern., 
. 21:1766-1768 0.975). 
51. Syva, C6rp., Emit Antiepileptic Drug Assays, Palo 
Alto, CA, 1975. 
52. Syva Corp., Syva Timer/Printer, Palo Alto, CA, 1975. 
.. 
:'1 
. I 
,: i 
i 
l• I 
'· ,., 
, I 
\" 
. ., 
109 
53. Syva Corp., Syva PipettorfDilutor, Palo Alto, CA, 1975. 
54. Ritschel, W. A., Handbook of Basic Pharmacokinetics, 
Drug Intelligence Publication-,-I-nc., Hamil ton, IL, 
1976, pp. 238-240. 
55. Wagner, John G., Biopharmac~eutics and Relevant Pharmaco-
kinetics, Drug Intelligence Publication, Inc., 
Hamilton, IL, 1971, p. 18L· 
56. .2£· ~it., (26)1, p. 67L 
57. Ibiq., (26), pp. 373, 650. 
58. Anon., J. Pharmacokinet. Biopharm., 2:433~466 (1974). 
-
·T• 
;;,i' 
,;. 
'l .~· '· 
,_, ... 
f ~ ~.'· 
)_. 
----------------------------------------------------.__.._,. • ._._._~-.~r•-~'~WW w. 
APPENDIX 
Glossary of Terms (58) 
Drug Product 
Chemical equivalents 
Pharmaceutical 
equivalents 
Bioavailability 
Bioequivalents 
Therapeutic 
equivalents 
Interchangeable drug 
products 
A dosa~e form 66ntainirtg 6rie or 
more active therapeutic ingredients 
along with other substances incl~ded 
during the manufacturing process .. 
Drug products that contain the.same 
amounts of the same therapeutically 
active ingredients in the same dos-
age forms and that meet present com-
pendia! standards. 
Drug products that contain the same 
therapeutically active ingredients 
in the same dosage forms and that 
meet standards to be established on 
the basis of the b~st available 
technology, 
The extent and rate ·of absorption 
from a dosage form as reflected by 
the concentration-time curve of the 
administered drug in the systemic 
circulation. 
Chemical equivalents which, when 
administered to the same individuals 
in the same dosage regim~n) will 
result in comparable bioavailabil1.ty. 
Chemical equivalents which, when 
administered to the same individuals 
in the same dosage ~egimen, will 
provide essentially the same efficacy 
and/or toxicity. 
·Pharmaceutical equivalents or hie-
equivalents that are accepted as 
therapeutic equivalents. 
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